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1. Introduction 
Humans enjoy a unique dominance over plants and animals. This dominance 
advanced with the development of a complex and adaptive central nervous system 
(CNS). CNS, comprising of the brain and spinal cord, is vital for integration and 
processing of information to achieve coordinated functioning of an organism. The 
human brain is a complex organ made up of two major cells types; neurons and glia. 
Neurons are considered to be the building blocks of the CNS and therefore 
degeneration of neurons leads to gross impairment. A physiological state would 
require homeostasis of the 1011 neuronal cells regulated by upto 10-50 times more 
numbers of glial cells, followed by cooperative functioning between nervous systems 
and motor coordination. However, several factors could lead to degeneration of 
neurons. Neurodegeneration can be caused by external factors such as trauma and 
pathogens or internal factors such as misfolded proteins, genetic mutations or 
inappropriate functioning of supportive cells in the CNS - such as microglia, 
astrocytes or oligodendrocytes. Microglia in particular have already been implicated 
as key players in brain injury as well as disease by several researchers (reviewed by 
Kreutzberg 1996)(Kettenmann et al. 2011) Understanding the factors involved in 
neurodegeneration on a cellular level is necessary to develop successful therapies 
against neurodegenerative diseases. 
1.1 Microglia: characteristics and functions 
Microglia, the smallest of the glial cells, are distributed in the brain and spinal cord 
and account for 20 % of the total population of glial cells in the CNS (Kreutzberg 
1996). The origin of microglia has been recently confirmed by the group led of Florent 
Ginhoux (Ginhoux et al. 2010) who conducted fate mapping studies in mice. Ginhoux 
and colleagues proved that adult mouse microglia develop from yolk-sac derived 
primitive myeloid progenitors that arise before embryonic day 8, during the first wave 
of hematopoiesis (figure 1, top). These microglial precursors then invade the entire 
CNS, setting up connections with other neural and glial cells (Ransohoff & Cardona 
2010). Following microglial invasion of the CNS, the blood brain barrier develops, 
leading to the isolation of microglia exclusively in the CNS. Subsequent to this event, 
peripheral nervous immune cells develop. Therefore there are regional as well as 
temporal distinctions between microglia and their counterparts in the peripheral 
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nervous system (PNS). The immune cells of the PNS include among others, 
monocytes and macrophages. These cell types arise from the second wave of 
hematopoiesis, namely - the definitive hematopoiesis (figure 1, bottom). 
 
Figure 1: Origins of microglia and macrophages. Microglial cells develop during the 
first wave of hematopoiesis (primitive) around embryonic day 7.5, in mice. The primitive microglia 
invade the CNS prior to formation of blood-brain barrier. After which, they mature into the final cell 
type in the company of neural cell types (top). Macrophages and monocytes develop during the 
second wave of hematopoiesis (definitive) around embryonic day 12.5, in mice. These cells 
represent the first immune effector cells of the PNS (bottom).  
Therefore, microglia are considered to be the only resident immune cells of the CNS, 
while peripheral immune cells are visitors that may temporarily support microglia in 
immune responses during pathogenesis. While microglial and their peripheral 
counterparts partially differ in their origins, the final cell types are rather 
indistinguishable. Both microglia and macrophages are immune reactive cells which 
express a comparable array of receptors and functional characteristics. Under 
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physiological conditions microglia actively survey the CNS to maintain homeostasis 
(Nimmerjahn et al. 2005). Other physiological functions include synaptic pruning 
during development and extracellular signaling via cytokines and chemokines to 
contact other cell types in the CNS which help maintain homeostasis (Tremblay et al. 
2010). Therefore, microglia are involved in many aspects of brain functioning and are 
required to maintain a healthy environment for neuronal signaling. During 
development microglia are directed by chemical cues to trim excess neuronal 
synapses in order to fine tune connections in the CNS. After development, when 
stimulated by chemo- or cytokines from apoptotic cells, microglia phagocytose debris 
and maintain homeostasis. Besides physiological functions, these cells play a 
defensive role in immune-compromised conditions such as infectious attack or 
trauma to the CNS (Kreutzberg 1996). Therefore, they are regarded to be immune 
effector cells of the CNS.  
Microglial immune responses can follow contradictory pathways depending on the 
type of stimuli they receive (figure 2). During development and homeostasis, 
microglia are most often stimulated by anti-inflammatory factors, which direct the 
microglia to follow a neuroprotective pathway through an arginase-dependent 
metabolism in which arginine leads to tissue repair. On the other hand, when 
stimulated by lipopolysaccharides (LPS) from invading gram-negative bacteria or by 
other pro-inflammatory factors, microglia follow a pro-inflammatory pathway which 
includes production of reactive oxygen species (ROS) (Bosurgi et al. 2011). Acute 
inflammation is necessary for removal of invading pathogens but also causes 
collateral damage to neighboring healthy cells. Furthermore, chronically persistent 
inflammation causes gross degeneration which can gradually spread throughout the 
CNS. 
Due to its importance in maintaining homeostasis in the CNS, pathological 
developments caused by intrinsic factors often include microglial dysfunction. 
Malfunctioning microglia are associated with many neurodegenerative diseases such 
as Alzheimer’s disease (AD), Parkinson’s and Huntington’s disease. Although the 
specific cause or effects regarding microglia in neurodegenerative diseases are not 
clearly understood, the capacity of microglia to exhibit both pro- and anti-
inflammatory properties (Mclaurin & Ransohoff 2010) are hypothesized to 
unintentionally support disease progression.  
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Figure 2: Contrasting microglial responses. The immune response elicited by microglial 
cells depends on the type of stimuli they receive. Stimuli from anti-inflammatory factors elicit a 
neuroprotective response (left) with the production of neurotrophic growth factors such as BDNF 
and GDNF. While stimuli from invading bacteria and other pathogens elicit a pro-inflammatory 
response (right) characterized by the production of radicals and pro-inflammatory cytokines. 
BDNF - brain derived neurotrophic factor; GDNF - glial cell line derived neurotrophic factor; IFN - 
interferon; IL - interleukin; LPS - lipopolysaccharide; M-CSF - macrophage colony stimulating 
factor; NO - nitric oxide; ROS - reactive oxygen species; SIGLEC - sialic acid binding 
immunoglobulin-like lectin; TGF - transforming growth factor; TLR - toll like receptor; TNF - tumor 
necrosis factor. 
1.2 Microglia in AD 
Microglial cells are a major source for radical and pro-inflammatory cytokine 
production in the CNS, which could lead to neuroinflammation. Since inflammation is 
a critical feature of AD, the contribution of microglia to AD onset and progression is in 
the focus of AD research (Heppner et al. 2015). AD brains develop widespread 
cortical atrophy leading to cognitive disabilities and memory loss. Pathological 
features include presence of amyloid plaques and neurofibrillary tangles. The former 
are dense, insoluble deposits of amyloid-β (Aβ) peptides accumulated in the 
extracellular space, while the latter refers to aggregates of microtubule-associated 
protein tau which are hyperphosphorylated and accumulate intracellularly in neurons 
(figure 3).  
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Figure 3: Pathological features of Alzheimer’s disease (AD) brain. In comparison 
to a healthy non-demented brain (left), the brain of an AD patient (right) shows clear atrophy and 
shrunken grey matter. On a microscopic level, plaques of Amyloid beta (Aβ) and 
hyperphosphorylated tau fibrils can be found extracellularly and intracellularly in neurons, 
respectively. Image of healthy brain was obtained from Servier powerpoint Image Bank. 
 
In general, microglia seem to play an ambivalent role in AD brains. On the one hand, 
they express receptors like Cluster of Differentiation (CD) 14 and toll-like receptors 2 
and 4 (TLR 2 and TLR 4) which should support clearance of Aβ plaques (Linnartz et 
al. 2010). Overall, studies show an increase in reactive microglia specifically localized 
around amyloid plaques in AD brains (Solito & Sastre 2012). In fact, a correlation 
between increased microglial reactivity with hightened amyloid load and cognitive 
impairment has been established (Edison et al. 2008). However, on the other hand, 
Aβ plaques increasingly accumulate and do not effectively get phagocytosed by the 
reactive microglia and therefore exacerbate disease progression.  
Hellwig and colleagues clearly showed that accumulation and formation of amyloid 
plaques occurred more readily in organotypic hippocampal slices depleted of 
microglia (Hellwig et al. 2015). Since microglial ablation leads to increased plaque 
formation, it can be concluded that microglia are vital in keeping Aβ plaques in check. 
This conclusion was further confirmed when they showed that replenishing the 
microglial-ablated organotypic cultures with microglia from wildtype (WT) mice 
reversed plaque formation. Most interestingly, when the microglial-ablated 
organotypic cultures were replenished with microglia from an AD model mouse, the 
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Aβ plaques formation was once again increased (Hellwig et al. 2015). These results 
suggest that the functional capabilities of microglia in an AD model are diminished 
possibly due to chronic reactivity to fibrillary Aβ. While healthy microglia as well as 
microglia in the early stages of amyloid formation are still capable of phagocytosing 
the plaques, microglia chronically exposed to the ever increasing plaque load lose 
their ability to effectively phagocytose Aβ plaques.  
 
In addition to faulty phagocytosis of Aβ by microglial cells, radical production by 
microglia has also been described as a feature of AD (Perry 2002, Ansari et al., 2010 
and Zhang et al., 2013). Studies on post-mortem AD brains as well as AD mouse 
models describe increased radical production in comparison to healthy controls. 
Although, the full contribution of radical damage towards neurodegeneration with 
respect to AD was initially controversial, studies now describe neuroinflammation as 
a constitutive event in AD brains (Solito et al., 2012, Heneka et al., 2015). 
Neuroinflammation is a result of chronic up regulation of pro-inflammatory factors and 
radical bursts by reactive astrocytes and microglia. In fact, microgliosis has been 
identified in AD irrespective of the presence of Aβ plaques (Edison et al. 
2008)(Yokokura et al. 2011)(Varnum & Ikezu 2012). Therefore, publications 
describing radical bursts upon treatment with Aβ must be viewed critically. Studies 
which claim that Aβ causes neuronal damage due to the induction of pro-
inflammation make use of high concentrations of Aβ (Milton et al. 2008)(Parajuli et al. 
2013). However, these studies do not appropriately mirror the in vivo environment of 
AD onset since Aβ accumulation is a slow and gradual process.  
Furthermore, studies which attribute the onset of AD solely to Aβ accumulation no 
longer hold relevance in view of the recent discovery of AD risk alleles through 
genome-wide association studies (GWAS). Late onset AD (LOAD) was previously 
considered to occur spontaneously, as a consequence of several external factors in 
combination with aging. In 2010, a new breakthrough in LOAD research was brought 
about by GWA). GWAS identified associations between polymorphisms of several 
novel genes with LOAD (Hollingworth et al. 2011)(Naj et al. 2011)(Shi et al. 2012). 
Among these, of particular interest in this project, is an immune-related gene- sialic-
acid binding immunoglobulin-like lectin 3 (SIGLEC3).  
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1.3 Immune receptors in health and disease 
SIGLEC3 encodes a protein expressed on the surface of immune cells and plays a 
role in the innate immune system. SIGLEC3, also known as CD33, binds sialylated 
molecules and signals via intracellular immunoreceptor tyrosine-based inhibitory 
motifs (ITIM). Ligand binding facilitates phosphorylation of the receptors’ intracellular 
tyrosine by Src kinase. Phosphorylated tyrosine serves as a docking site for tyrosine 
phosphatases such as Src homology region 2 domain-containing phosphatase-1 
(SHP-1) which in turn dephosphorylate downstream molecules of the activatory 
signaling pathway. By this way, SIGLEC3 can modulate the downstream molecules 
of activation receptors, such as triggering receptor expressed on myeloid cells 2 
(TREM2), to gradually dampen activation/inflammation and maintain homeostasis 
(figure 4) (reviewed in Linnartz-Gerlach et al. 2014).  
 
Therefore, SIGLEC3 modulates cellular activation and serves to fine tune the cellular 
response to stimuli. SIGLEC3 is primarily expressed on cells of myeloid lineage. 
Therefore, microglia are the only resident immune cells in the CNS which express 
this receptor. Taking into account the association between polymorphisms of CD33 
and LOAD, the hypothesis of microglial activities contributing to disease progression 
is gaining interest. While the polymorphism rs3865444C of SIGLEC3 has been 
associated with increased LOAD risk, the polymorphism rs12459419T has been 
recently identified to be protective against LOAD onset (Griciuc et al. 2013).  
 
The final gene of interest in this project having polymorphisms associated with AD is 
trem2. TREM2, as the name suggests, is expressed on myeloid type cells such as 
microglia and macrophages. TREM2 in association with the intracellular activatory 
receptor DAP12 can mediate phagocytosis of apoptotic neurons without 
inflammation. GWAS have identified a rare missense mutation in the gene encoding 
TREM2, called the R47H substitution (Wang et al. 2015)(Colonna & Wang 2016). 
Recent studies have identified that the R47H mutation reduces the binding ability of 
TREM2, hindering phagocytosis and therefore perhaps allowing Aβ to accumulate 
(Wang et al., 2015). APOE has been described to be a ligand of TREM2 which can 
bind Aβ. However, when the binding affinity of TREM2 to its ligand is compromised, 
the delivered Aβ cannot be consequently phagocytosed. 
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All in all, polymorphisms of several genes have been associated with increased 
LOAD risk. Interestingly, a high number of these genes are transcribed in immune 
cells. The compromised ability to phagocytose when faced with Aβ plaques seems to 
be a repeated facet of LOAD risk. Both proteins described above; SIGLEC3 and 
TREM2 are involved in immune response by modulating phagocytosis. Therefore, an 
event of Aβ accumulation by the malfunctioning of one or more of these genes is 
highly possible.  
 
Figure 4: Inhibitory (ITIM) versus activatory (ITAM) signaling. Upon ligand binding 
to inhibitory receptors, such as certain members of the SIGLEC family, intracellular tyrosine motif 
gets phosphorylated by tyrosine phosphatases and serves as a docking site for SHP1. As a 
consequence, the phosphorylated-downstream molecules of the activatory pathway are 
dephosphorylated and therefore cannot further propagate activation of cellular process, such as 
phagocytosis and proliferation. ITIM - immunoreceptor tyrosine-based inhibitory motif; ITAM - 
immunoreceptor tyrosine-based activatory motif; shp - src homology region 2 domain-containing 
phosphatase 1; p - phosphate; Aβ - amyloid beta; ApoE - apolipoprotein E; TREM2 - triggering 
receptor expressed on myeloid cells 2; DAP12 - TYRO-protein tyrosine kinase-binding protein 12; 
syk - spleen tyrosine kinase.  
Immune cells, by means of their expressed receptors, are currently in the focus of AD 
research. Especially malfunctioning receptors that unintentionally propagate disease 
progression are being extensively researched as putative therapeutic targets, as 
described above. However, the respective microenvironment that plays a critical role 
in the maintenance and functioning of all cell types, on a molecular level must not be 
overlooked. With this in mind, glycobiology - the study of sugars - has been included 
in this project as a vital theme involved in malfunctioning immune cells with respect to 
AD development and progression.  
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1.4 Sialic acids  
Previous studies (Samraj et al., 2014, Ma et al., 2016) have already reiterated the 
influence that different types of sugars or sialic acids have on the functioning of 
various cell types, including, immune cells. In fact, it is now known that the 
incorporation of a foreign sialic acid can lead to inflammation called “xenosialitis” 
(Samraj et al. 2015). Therefore, the fact of developing chronic inflammation, a 
hallmark of AD, which could be caused by xenosialitis is a topic worth investigating 
further. To first understand the depths of the influence sugars have on our cells, their 
molecular and structural characteristics must be studied. 
Sialic acids are a family of sugars on a nine-carbon backbone that are primarily found 
at the ends of glycan chains on the surface of all cell types. N-acetylneuraminic acid 
(Neu5Ac) is one of the most common and basic forms of sialic acids from which N-
glycolylneuraminic acid (Neu5Gc) and other more complicated sialic acids can be 
derived. Neu5Ac differs from Neu5Gc by a hydroxyl group (figure 5, right). They form 
glycoproteins or glycol lipids by α-2,3-; α-2,6 or α-2,8 linkages (Varki 2007). Sialic 
acids play a role in differentiation, growth, cell-cell interactions and signal 
transduction among other functions (Varki & Gagneux 2012). The highest 
concentration of sialic acids is found in the brain, where they are present mostly in 
the form of glycolipids (Collins et al. 1997).  
 
Figure 5: Loss of functional cytidine monophosphate-N-acetylneuraminic acid 
hydroxylase (CMAH) in humans. During evolution a 96 base pair deletion in gene cmah 
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resulted in humans being the only higher mammals to lack the ability to convert N-
acetylneuraminic (Neu5Ac) acid to N-glycolylneuraminic acid (Neu5Gc) (left). NAD+ / NADH – 
nicotinamide adenine dinucleotide. Neu5Ac can by hydrolyzed to give rise to Neu5Gc. Therefore 
the two sialic acids differ by a single oxygen atom (right). Structural images of Neu5Ac and 
Neu5Gc were modified from Wikipedia. 
Interestingly, sialic acids are found in the midst of an evolutionary race between 
vertebrates, which use these sialic acids to fine tune immune responses, and 
pathogens, which hijack host sialic acids to avoid immune response of the latter 
(reviewed by Varki 2007). The most notable evolutionary change with regards to 
sialic acids is the frame shift mutation in the cytidine monophosphate N-
acetylneuraminic acid hydroxylase (CMAH) gene caused by a 96-base pair deletion 
of exon 5 (Padler-Karavani, Hurtado-Ziola, et al. 2013). As a result, Neu5Ac cannot 
be converted to Neu5Gc (figure 5, left). Therefore, humans experienced a loss of 
Neu5Gc and accumulation of Neu5Ac and consequently, a change in several 
receptors which have evolved to recognize these sialic acids. These receptors have 
evolved to recognize specific types or forms of sialic acids in an attempt to fine tune 
immune responses (Varki 2010). Therefore, sialic acids that cover most proteins and 
lipids on the cell surface and their corresponding receptors are emerging as 
important structures in human physiology. SIGLECS are one such receptor family 
that is found primarily on the surface of immune cells and oligodendrocytes. The 
above described SIGLEC3 is a member of the SIGLEC family, with inhibitory 
signaling capacity in humans. 
Humans evolved to not produce Neu5Gc as an attempt to avoid pathogen infiltration 
using molecular mimicry. However, several studies have shown individuals to have 
antibodies against Neu5Gc (Padler-Karavani et al., 2013). In fact, Neu5Gc has been 
found in cancer tissue as well as in embryonic tissue. Naturally, the question arises - 
Where does this Neu5Gc originate from? Studies by Bardor and colleagues (Bardor 
et al., 2005) have extensively shown that Neu5Gc can be incorporated from 
metabolism by micropinocytosis or endocytosis. Since the uptake of the sialic acids 
occur in a non-receptor mediated manner, both sialic acids are pino-/ endocytosed in 
a non-biased manner. Neu5Ac and Neu5Gc enter the cell, either as free sialic acids 
or on glycoproteins. Sialic acids on proteins are first separated by lysosomal 
sialidases and then placed onto new proteins by sialyltransferases. The newly built 
glycoproteins are then transported to the cell surface to form a part of the glycocalyx 
11 
 
(figure 6). Once Neu5Ac and Neu5Gc are part of the glycocalyx, they are open for 
receptor binding (or rather mis-binding) leading to a malfunctioning of receptors that 
depend on sialic acids as endogenous ligands. The previously described SIGLEC 3 
is a member of the family of inhibitory SIGLEC receptors and as explained, binds 
sialic acid. Therefore, it can be postulated that incorporation of foreign sialic acids 
may negatively influence the binding and functioning of a sialic acid-binding receptor 
such as SIGLEC3. Considering correlation between SIGLEC3 and LOAD, by 
extension, it could be hypothesized that sialic acids may play a role in either LOAD 
development or progression. 
Therefore, this thesis focuses on the all-encompassing idea that incorporated sialic 
acids may influence the functioning of LOAD associated receptors which in turn may 
be causative or supportive of the neurodegenerative diseases. With this in mind, the 
concept followed in this project was to identify the influence of foreign sialic acids 
(Neu5Gc) in comparison to native sialic acids (Neu5Ac) on several typical aspects of 
microglia functioning. In order to mimic a pre-clinical AD environment, the cells were 
additionally exposed to nanomolar concentrations of Aβ. The Aβ concentration for 
this project was intentionally selected to be upto 10 times lower than described in 
previous publications (Milton et al. 2008; Parajuli et al. 2013), to serve as part of the 
cellular environment rather than to be a strong stimulation. Several read outs such as 
phagocytosis capacity, proliferative and apoptotic rate, reactive oxygen species 
(ROS) production and many more have been extensively studied. These studies 
could help identify the underlying cause of chronic inflammation as found in AD.  
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Figure 6: Mechanism of Neu5Gc incorporation. Neu5Gc can be metabolically 
incorporated in to the cell surface glycocalyx. Neu5Ac as well as Neu5Gc are taken up by pino- or 
endocytosis, as free sialic acids or in the form of glycoproteins. Once engulfed, the sialic acid-
bound glycoprotein is modified by means of lysosomal sialidases and sialyl transferases. The 
final product is re-introduced on the cell surface glycocalyx, where the sialic acids are exposed 
and available for receptor binding. Lectin family of receptors such as SIGLECs are capable of 
binding sialic acids.  
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1.5 Aim of Study 
Chronic inflammation is an undisputed feature of late onset Alzheimer’s disease 
(LOAD). Activated microglia,found around amyloid beta (Aβ) plaques are implicated 
as the source of inflammation. However they are incapable of efficiently 
phagocytosing the plaques and therefore lead to Aβ accumulation. The molecular 
mechanisms responsible for this ambivalent and ultimately neurodestructive behavior 
of microglia remains elusive. Studies show that the deposition of Aβ occurs in 
demented as well as non-demented individuals. Therefore, deposition of Aβ is not 
solely responsible for disease onset nevertheless accumulation of Aβ plaques 
possibly exacerbates LOAD progression. Furthermore, Genome-wide association 
studies (GWAS) have identified polymorphisms of several genes, including SIGLEC3 
and TREM2 found on microglia, which increase LOAD risk. Both proteins are 
involved either directly or indirectly with maintenance of homeostasis and 
phagocytosis. Therefore, it is conceivable that dysregulation of these proteins could 
cause inflammation and faulty phagocytosis as seen in LAOD patients.  
The objective of this project was to establish a human microglial model system to 
study SIGLEC3 signaling and SIGLEC3 receptor interaction with sialic acids in AD 
pathology. A human model system is critical since SIGLEC3 is highly species specific 
and therefore cannot be studied in animal models. As such, a protocol to differentiate 
microglia (iPSdM) from induced pluripotent stem (iPS) cells was optimized in the 
scope of this thesis. However, the cell numbers obtained were limited and hindered 
the extent of biochemical and functional analysis that could be performed. Therefore, 
THP1 human monocyte-derived macrophage cell line was used as a surrogate 
human model system to study the role of SIGLEC3 signaling. In this regard, the 
influence of an immunogenic sialic acid - Neu5Gc in comparison to sialic acid - 
Neu5Ac, serving as a ligand to SIGLEC3, on macrophage functions was analyzed. 
Furthermore, in order to mimic the environment of an AD brain on a molecular level, 
macrophages were also chronically treated with nanomolar concentrations of Aβ. The 
overall hypothesis of this thesis involves the comprehensive idea that chronic 
inflammation occurs as a result of persistently activated microglia due to improper 
SIGLEC3 signaling caused by Neu5Gc. The chronically malfunctioning microglia 
exacerbates neurodegeneration and elicits an inappropriate response to Aβ 
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deposition. Overall, this thesis aims at determining the underlying molecular 
mechanisms preceding clinically diagnosed LOAD. 
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2. Materials and Methods 
2.1 Materials 
 2.1.1 Cell lines 
JS-AF12 iPS induced pluripotent stem cell line, 
generated and kindly provided by 
AG Brüstle, University of Bonn, 
Germany 
  
SdMic 1 Induced pluripotent stem cell (JS-
AF 12) derived microglial line, 
generated based on protocol from 
the thesis of Dr. Kristin Roy 
  
SdMic 2 Induced pluripotent stem cell (JS-
AF 12) derived microglial line, 
generated based on protocol from 
the thesis of Dr. Kristin Roy 
  
THP1 wildtype monocytes (WT) kindly provided by the group of Prof. 
Hornung, University of Bonn 
  
THP1 SIGLEC3 knockout monocytes 
(SIG3 KO) 
kindly generated and provided by 
the group of Prof. Hornung, 
University of Bonn 
 
 
2.1.2 Chemicals and Reagents 
1,4-Diazobicyclo-(2.2.2)octan Sigma Aldrich Chemie GmbH, 
Germany 
  
Accutase (STREM Pro cell 
dissociation reagent) 
Gibco, Thermo Fischer scientific, 
USA 
  
Amyloid-beta, biotinylated Bachem, Germany 
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Amyloid-beta, non-biotinylated Peptide speciality laboratories, 
Germany 
Apo-transferrin, Human Sigma Aldrich Chemie GmbH, 
Germany 
  
Apo-transferrin, Bovine Sigma Aldrich Chemie GmbH, 
Germany 
  
Aqua Poly/Mount Polysciences Inc, USA 
  
β-Mercaptoethanol Gibco, Thermo Fischer scientific, 
USA 
  
B27 supplement (50x)               Gibco, Thermo Fischer scientific, 
USA 
  
Bovine serum albumin  Sigma Aldrich Chemie GmbH, 
Germany 
  
Collagenase , type IV Gibco, Thermo Fischer scientific, 
USA 
  
Chicken serum Gibco, Thermo Fischer scientific, 
USA 
  
ddH2O Filtered and autoclaved in-house 
 
 
 
D-(+)-Glucose solution (45 %) Sigma Aldrich Chemie GmbH, 
Germany 
 
 
 
DiI, cell tracker Life technologies, USA 
  
Dihydroethidium (DHE) Thermo Fischer scientific, USA 
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Dimethyl sulfoxide  Carl Roth GmbH & Co KG,, 
Germany 
 
 
 
DMEM/F12 (1:1) with L-glutamine 
and 15 mM HEPES 
Gibco, Thermo Fischer scientific, 
USA 
 
 
 
EDTA Carl Roth GmbH & Co KG,, 
Germany 
  
Ethanol Carl Roth GmbH & Co KG, 
Germany 
  
Fluoresbrite Polychromatic Red 
microspheres 1.0 µm 
Polysciences Incorporated, 
Germany 
 
 
 
Fibronectin from bovine plasma Sigma Aldrich Chemie GmbH, 
Germany 
 
 
 
Fibronectin 0.1 % solution Sigma Aldrich Chemie GmbH, 
Germany 
 
 
 
Fetal calf serum Gibco, Thermo Fischer scientific, 
USA 
 
 
 
Geltrex Thermo Fischer scientific, USA 
  
Knockout serum replacement Gibco, Thermo Fischer scientific, 
USA 
 
 
 
Laminin Sigma Aldrich Chemie GmbH, 
Germany 
 
 
 
L-Glutamine (200 mM) Gibco, Thermo Fischer scientific, 
USA 
  
LPS Invivogen, USA 
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Non-essential amino acids (10 mM) Gibco, Thermo Fischer scientific, 
USA 
 
 
 
N2 supplement (100x) Gibco, Thermo Fischer scientific, 
USA 
 
 
 
Normal goat serum Sigma Aldrich Chemie GmbH, 
Germany 
 
 
 
Paraformaldehyde  Merck Millipore, Germany 
 
 
 
PBS Gibco, Thermo Fischer scientific, 
USA 
  
Penicillin/Streptomycin Gibco, Thermo Fischer scientific, 
USA 
 
 
 
Phorbol 12-myristate 13-acetate 
 
Sigma Aldrich Chemie GmbH, 
Germany 
 
 
 
Poly-L-Lysine Sigma Aldrich Chemie GmbH, 
Germany 
 
 
 
Poly-L-Ornithin Sigma Aldrich Chemie GmbH, 
Germany 
 
 
 
ROCK Inhibitor Y-27632 Merck Millipore, Germany 
  
RPMI medium 1640 Thermo Fischer scientific, USA 
  
Sodium pyruvate (100 mM) Gibco, Thermo Fischer scientific, 
USA 
 
 
 
TritonX Sigma Aldrich Chemie GmbH, 
Germany 
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Trypsin (0.25 %) Gibco, Thermo Fischer scientific, 
USA 
 
2.1.3 Growth factors and Cytokines 
Recombinant human fibroblast 
growth factor 2 (rhFGF2) 
R&D Systems GmbH, Wiesbaden, 
Germany  
  
Recombinant human (rh) IL 34  Biolegend,BIOZOL, Germany 
  
Recombinant human Macrophage 
colony stimulation factors (rhMCSF) 
R&D systems, USA 
 
2.1.4 Buffers and Solutions 
4 % Paraformaldehyde 4 g Paraformaldehyde in 100 ml 
1x PBS 
  
10x Bovine serum albumin          10 g BSA in 100 ml 1 x PBS 
  
10x TBE 108 g Tris 
55 g boric acid 
40 ml 0.5 EDTA 
ad 1 l aqua bidest. 
  
EDTA 46.53 g EDTA 
170 ml aqua bidest. 
adjust pH 8.5 with 5 M NaOH 
ad 250 ml aqua bidest. 
  
MES SDS running buffer for 
western blot 
Novex, Life Technologies, USA 
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Poly-L-Lysine (5 µg/ml) 5 µg in 1 ml aqua dest. 
  
Poly-L-Ornithin (0.01 mg/ml) 9.2745 g boric acid ad 1 l aqua bi-
destilled 
100 mg Poly-L-Ornithin 
  
Restore Plus western blot stripping 
buffer 
Thermo Fischer scientific, USA 
  
Saccharose, 30 % 30 % saccharose  
0.1 % sodium azide 
add 500 ml PBS 
  
Transfer buffer for western blot Novex, Life Technologies, USA 
  
Tris buffer, 0.2 mM pH 8.5 24.765 g in 150 ml aqua bidest. 
adjust pH 
 
2.1.5 Kits 
RNeasy Mini Kit Qiagen 
  
SuperScript First-Strand Synthesis 
Systme 
Invitrogen 
  
Blood and tissue kit Qiagen 
 
2.1.6 Media 
B27 differentiation 
medium 
APEL medium (StemCell technologies) 
2 % B27 
20 ng/ml rhFGF2 
5 µg/ml fibronectin 
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freezing medium 50 % KO-SR 
40 % medium 
10 % DMSO 
  
iPS-differentiation 
medium 
DMEM/F12 (1:1) with L-glutamine with HEPES 
(15 mM) 
20 % knockout serum replacement 
0.1 mM NEAA 
0.1 mM L-glutamine 
N2 differentiation 
medium 
APEL medium (StemCell technologies) 
1 % N2 supplement 
20 ng/ml rhFGF2 
10 ng/ml laminin 
  
N2 medium  DMEM/F12 (1:1) with L-glutamine with HEPES 
(15 mM) 
1 % N2 supplement 
0.5 mM L-glutamine 
5.3 µg/ml D-glucose 
100 µg/ml penicillin/streptomycin 
  
TESR-E8 medium Stem cell technologies 
  
THP1 medium for 
monocyte culture 
RPMI medium1640 (500 ml) 
1 % chicken serum 
1 % sodium pyruvate 
1 % L-glutamine 
1 % penicillin/streptomycin 
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1 % N2 supplement 
  
THP1 
experimentation 
medium  
RPMI medium1640 (500 ml) 
1 % sodium pyruvate 
1 % L-glutamine 
1 % penicillin/streptomycin 
1 % N2 supplement 
 
 2.1.7 Consumable supplies 
6-well Tissue Culture Plate Cellstar, Greiner Bio One, Germany 
  
96-well optical bottom plates Thermo Fischer scientific, USA 
  
Bacterial dishes (100 mm) Corning incorporated, USA 
  
Cell Scraper Sigma Aldrich Chemie GmbH, 
Germany 
  
Cryovials (2 ml) Sarstedt Ag & CoKG, Germany 
  
Falcon tubes (15 ml) Cellstar, Greiner Bio One, 
Frickenhausen, Germany 
  
Falcon tubes (50 ml) Sarstedt Ag & CoKG, Germany 
  
Filtropur (0.25 µm, 0.4 µm) Sarstedt Ag & CoKG, Germany 
  
Graduate pipette Tipps (10 µl, 
100 µl, 1000 µl) 
Starlab GmbH, Ahrensburg, Germany 
  
Lab-Tek Chamber Slide w/ 
Cover Permanox Slide Sterile 4 
Thermo Fischer scientific, USA 
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Well 
  
Microscope cover glasses P. Marienfeld GmbH, Germany 
  
Needles Sterican, Braun Meisungen AG, 
Germany 
  
Nitrile gloves Meditrade, Germany 
  
Pasteur pipettes Brand GmbH & Co KG, , Germany 
  
Pipettes (5 ml, 10 ml, 25 ml) Corning incorporated, USA 
  
Safe-seal micro tubes (0.5 ml, 
1.5 ml, 2 ml) 
Sarstedt Ag & Co KG, Germany 
  
Syringes (5 ml, 10 ml) Omnifix, Braun Meisungen AG, 
Germany 
  
Tissue Culture Dishes (35 mm, 
60 mm, 100 mm) 
Sarstedt Inc., USA 
  
Tissue Culture Flask (75 cm3, 
25 cm3) 
Sarstedt Inc., USA 
  
Vacuum driven disposable bottle 
top filter 
Merck Millipore, Germany 
 
 
2.1.8 Technical equipment  
- 20°C freezer Liebherr, Switzerland 
  
+ 4°C fridge Liebherr, Switzerland 
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BD FacsCalibur BD Biosciences, USA 
  
BD FacsCanto II BD Biosciences, USA 
  
Cell MateII (pipette boy) Thermo Fisher Scientific Inc., USA 
  
Eppendorf Mastercycler epgradient S Eppendorf 
  
Hera cell 150 (incubator) Heraeus Holding GmbH, Germany 
  
Hera freeze (- 80°C freezer) Heraeus Holding GmbH, Germany 
  
Hera safe (laminar-air flow 
workbench) 
Kendro Laboratory Products 
GmbH, Germany 
  
Mefaguge1.0R (centrifuge) Heraeus Holding GmbH, Germany 
  
Microscopes Carl Zeiss AG, Germany 
 HBO 50/AC 
 Axiovert200M 
 ImagerZ1 
  
Micropipettes (10µl, 100µl, 1000µl) Eppendorf AG, Germany 
  
Systec D-150 (autoclave) Systec GmbH, Germany 
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Thermomixer compact Eppendorf AG, Germany 
  
Water bath WB/OB7-45 Memmert GmbH & CoKG, 
Germany 
 
 2.1.9 Software 
BD CellQuest Pro BD Biosciences, USA 
BD FACS Diva BD Biosciences, USA 
FlowJo FlowJo LLC, USA 
Fluoview ver.3.1 Olympus corporation 
ImageJ NIH, USA 
ImageLab Bio-Rad, Germany 
Olympus FluoView1.4 Olympus, Germany 
SPSS SPSS Inc., USA 
Wallac Envision manager PerkinElmer, USA 
2.2 Methods 
 2.2.1 Culture of induced pluripotent stem cells 
Induced pluripotent stem (iPS) cells were cultured on a layer of geltrex matrix in 
TESR-E8 medium. The iPS cells grow in colonies and when the colonies covered 
about 70% of the surface, they were passaged using accutase. For passaging, 
colonies were treated with accutase for 3 minutes. The detached single cells were 
collected in a falcon tube and centrifuged at 1000 rpm, for 3 minutes. The cell pellet 
was resuspended in fresh TESR-E8 medium and plated onto a new matrix-coated 
culture plate in the presence of 10 µM ROCK inhibitor for the first 24 hours after 
passaging. After 24 hours, medium containing ROCK inhibitor was replaced with 
fresh pre-warmed TESR-E8 medium. 
2.2.2 Generation of induced pluripotent stem cell derived microglial cell lines 
(iPSdM) 
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Differentiation was initiated by detaching intact colonies using 1 mg/ml collagenase. 
The colonies were centrifuged at 1000 rpm, for 3 minutes and the supernatant was 
discarded. The cell pellet was very gently resuspended, to maintain the colonies 
intact, in iPS-differentiation medium and placed in non-adherent bacterial culture 
dishes to support 3-D formation of embryoid bodies (EBs). The EBs were maintained 
in suspension culture for eight days. On the final day of suspension culture, a few 
EBs were analyzed for the expression of KDR (1:5, anti-human KDR-FITC) and 
CD235a (1:50, anti-human CD235a-APC) positive cells, by flow cytometry. The 
remaining EBs were then plated onto PLO/Fn coated culture dishes in B27 
differentiation medium (section 2.1.6) and maintained for 14 days, with media 
changes as necessary. For the first two days in B27 differentiation media, the 
differentiating cells were stimulated with 50 ng/ml IL-34. The culture media was then 
switched to N2 differentiation (section 2.1.6), for a further 10 days. For the first two 
days in N2 differentiation media, the differentiating cells were stimulated with 50 
ng/ml IL-34. Finally, the cells were cultured in N2 medium without supplementation. 
The differentiation plates were supplied with fresh N2 medium as necessary and 
maintained in culture until the appearance of microglia was observed. Microglia were 
morphologically identified as round-shiny cells with a size of 30 - 40 µm. At the 
appearance of a few round-shiny cells, the differentiation plate was stimulated for 48 
hours with IL-34 (100 ng/ml) to support the expansion of the cells of interest. Once 
several thousand cells appear, the round-shiny cells can be manually isolated with 
the help of a micropipette and bright-field microscope under a sterile, horizontal 
hood.  
All analyses were carried out on PLL-coated 96-well optical-bottom plates and using 
confocal microscopy. The morphologically identifiable round-shiny microglial cells 
were manually isolated from the differentiation plate using a micropipette. The 
isolated cells were distributed in a 96-well plate and stimulated with IL-34 (100 ng/ml) 
for the first 24 hours after isolation 
2.2.3 Proliferation assay for iPSdM 
Proliferative capacity of cells was analyzed by measuring the incorporation of Ki67. 
The cells were fixed for 10 minutes by 4 % PFA followed by washing and blocking in 
10 % BSA supplemented with 0.5 % NGS and 0.1 % Triton-X-100, for 60 minutes at 
room temperature. After blocking, the cells were co-stained overnight with primary 
27 
 
antibodies against Ki67 and IBA-1, at 4 °C (table 1). Cells were then stained with 
corresponding secondary antibodies (table 1) for 2 hours at room temperature, 
protected from light. Finally, the nuclei of the cells were stained with 1:10,000 DAPI 
for 30 seconds. After washing three times in 1x PBS, cells were stored in 1x PBS and 
imaged immediately by confocal microscopy. Analyses were performed using ImageJ 
software.  
2.2.4 Immunocytochemical analysis for microglial markers 
The isolated microglial cells were placed a 96-well optical bottomed plate and fixed 
with 4 % PFA for 10 minutes. Following fixation, cells were blocked for 60 minutes at 
room temperature with 10 % BSA supplemented with 5 % NGS and 0.1 % Triton-X-
100. The primary antibodies were added overnight at 4 °C (table 1). Respective 
secondary antibodies were stained for 2 hours at room temperature, protected from 
light (table 1). Cells were then kept in 1x PBS and imaged immediately by confocal 
microscopy. Analyses were performed using ImageJ software.  
Table 1: Antibodies for immunocytochemical analysis of iPS-derived microglia 
Primary antibody (concentration) Secondary antibody 
(concentration) 
CD11b (5 µg/ml) 
BD biosciences, 553307  
PE anti-rat (5 µg/ml) 
  
TREM2 (5 µg/ml) 
R&D systems, mab1828  
PE anti-mouse (5 µg/ml) 
  
Ki67 (1:100) 
Millipore, AB9260  
PE anti-rabbit (5 µg/ml) 
  
IBA-1 (1:500) 
Wako, 019-19741 
PE anti-rabbit (5 µg/ml) 
 
 2.2.5 Culture of THP1 monocytes and macrophages 
Wildtype (WT) as well as SIGLEC3 Knockout (SIG3 KO) THP1 monocytes were 
generously contributed by Prof. Hornung (University of Bonn). SIG3 KO cells were 
obtained by crispr-cas9 technology, causing a four base pair deletion in Exon 3 (base 
pair 566 to base pair 569). The deletion disrupts translation of the modified gene into 
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a functional protein. The SIG3 KO cells are a 100 % devoid of functional protein 
SIGLEC3. 
Monocytes were obtained in RPMI medium supplemented with 10 % FCS, 2 mM L-
glutamine, 1 mM sodium pyruvate and 100 µg/ml penicillin/streptomycin. However, 
further culturing was performed in modified medium adapted to contain only 
acetylated sialic acids (human-like). For this purpose, culturing was carried out in 
RPMI medium supplemented with 1 % Chicken Serum, 0.2 mM L-glutamine, 1 mM 
sodium pyruvate, 100 µg/ml penicillin/streptomycin and 1 % N2 supplement. 
Experimentation was performed on monocyte-derived macrophages. THP1 
macrophages were obtained from monocytes by plating a defined number of cells in 
culture plates with 10 ng/ml PMA, for 48 hours. After 48 hours, PMA is washed out of 
the culture by washing cells three times with sterile PBS. Washed cells were then 
cultured in respective sialic-acid containing medium, as described below. 
2.2.6 Sialic acid feeding and chronic amyloid β exposure - experimental setup 
For experimentation, monocyte-derived macrophages were cultured in THP1 
experimentation containing 0.2 mM L-glutamine, 1 mM sodium pyruvate, 1 % N2 
supplement and 100 µg/ml penicillin/streptomycin. As controls, cells were cultured in 
THP1 experimentation medium without sialic acid supplementation (SDm). Samples 
include culturing cells in THP1 experimentation medium supplemented with either 6 
µM Neu5Ac (ACm) or 6 µM Neu5Gc (GCm). Both Neu5Ac and Neu5Gc were 
delivered to the cells in the form of protein-bound sialic acid. Appropriate 
concentration of apo-transferrin bound Neu5Ac and apo-transferrin bound Neu5Gc 
were supplemented in the cell culture to obtain a final concentration of 6 µM Neu5Ac 
or 6 µM Neu5Gc, respectively. Fresh medium was exchanged every alternative day 
for a total of 6 days.  
Additionally, a day after having started the sialic acid supplementation, cells were 
either left untreated or treated with 0.25 µM non-biotinylated amyloid β (nbAβ). 
Chronic exposure was achieved by adding Aβ every day, until day 6. On day 6, 
respective experiment was performed.  
Preparation of Aβ, for chronic treatment was performed as follows. The non-
biotinylated Aβ was commercially obtained from Peptide specialty laboratories in the 
form of lyophilized powder. Lyophilized Aβ was resuspended in sterile water to a 
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concentration of 1100 µM and stored at -20°C. Before addition to the cell culture, Aβ 
was incubated at 37°C for 7 days with vortexing every day for 2 - 3 minutes. Pre-
incubated Aβ was then diluted to 100 µM in sterile water and stored as aliquots at -
20°C. Aliquots were thawn and vortexed prior to use in cell culture.  
Table 2: Experimental Setup for sialic acid feeding and chronic Aβ treatment 
day x - 2 differentiate monocytes into macrophages by 10 ng/ml PMA treatment for 48 
hours 
  
day 0 wash out PMA and culture cells in respective sialic-acid supplemented medium 
(SDm, ACm or GCm) 
  
day 1 untreated or 0.25 µM nbAβ 
  
day 2 media change with respective sialic acid supplementation, 
untreated or 0.25 µM nbAβ 
  
day 3 media change with respective sialic acid supplementation, 
untreated or 0.25 µM  nbAβ 
  
day 4 media change with respective sialic acid supplementation, 
untreated or 0.25 µM nbAβ 
  
day 5 media change with respective sialic acid supplementation, 
untreated or 0.25 µM nbAβ 
  
day 6 Experimentation 
 
2.2.7 HPLC 
The incorporation of Neu5Ac and Neu5Gc from the respective supplemented 
medium was analyzed by xCGE-LIF (multiplexed capillary gel electrophoresis with 
laser-induced fluorescence detection) and Flow cytometry. 
 For xCGE-LIF analyses, 5 x 105 cells were seeded per well of a 6-well plate. One 
well was seeded per condition, as described in table 2. On day 6, cells were scraped 
and pelleted by centrifugation at 1300 rpm, for 3 minutes. Supernatant was discarded 
and the pellets were resuspended in 200 µl RIPA buffer containing 2 µl HALT 
protease-phosphatase inhibitor cocktail. The cell suspensions were stored at -80°C 
30 
 
till analysis. Three repeats of the above described procedure were performed. xCGE-
LIF analysis was performed in cooperation with collaborators at the Max Planck 
Institute for Dynamics of Complex Technical Systems, Magdeburg. In short, the 
precipitated proteins were concentrated by affinity-solid phase extraction and 
separated on a 2-D gel electrophoresis system. The bands were then cut out and the 
N-glycan structures were extracted from the gel, in water by PNGase F enzyme 
activity. The extracted N-glycans were then fluorescently labeled with APTS (9-
aminopyrene-1,4,6 trisulfonic acid) and run on a UPLC system to detect the Neu5Ac 
and Neu5Gc present on the N-glycan structures.  
2.2.8 RNA sequencing analysis 
RNA sequencing analysis of samples from cells cultured in SDm, ACm and GCm 
were performed by the group of Prof. Joachim Schultze (University of Bonn, Limes). 
After the six day culture (table 2), each sample was centrifuged to obtain cell pellets. 
Cell pellets were then resuspended in 1 ml Qiazol each and stored at -80°C before 
RNA extraction, measurement and analysis. RNA sequencing was performed for the 
three out of four individual samples with the highest quality, as measured using 
TapeStation. In short, template libraries were made from double stranded cDNA 
molecules obtained from total RNA. Further downstream processing and analysis 
were performed as described by the following publications; (Fujita et al. 
2011)(Trapnell et al. 2009)(Trapnell et al. 2010)(Langmead et al. 2009) and (Trapnell 
et al. 2012).   
2.2.9 Flow cytometry analyses 
Cell numbers and antibodies used are specific to each experiment as described in 
table 3. 
For flow cytometry analysis of Neu5Gc incorporation, chicken polyclonal antibody 
directed against Neu5Gc was used. 1 x 106 cells were seeded per well of a 6-well 
plate, one 6-well plate was seeded per cell line (WT and SIG3 KO). On 
experimentation day, cells were scraped and pelleted by centrifugation at 1300 rpm, 
for 3 minutes. The pellets were resuspended in diluent buffer with or without 1:500 
Neu5Gc antibody, as provided by the manufacturer. Primary antibody staining was 
performed at room temperature for 1.5 hours. Cells were washed by centrifugation. A 
secondary antibody, biotin anti-chicken (5 µg/ml) was added for 45 minutes, on ice. 
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Cells were washed by centrifugation. A fluorescently labeled tertiary antibody, PE-
streptavidin (5µg/ml) was added for 30 minutes on ice, protected from light. Relative 
fluorescence intensity was measured by Flow cytometry and analyses were 
performed using FlowJo software.  
For calculating cis-bound SIGLEC3 as well as surface marker analysis, 1 x 106 
cells were seeded per well of a 6-well plate. One 6-well plate was seeded per cell line 
(WT and SIG3 KO). On experiment day, macrophages were washed once with sterile 
1x PBS to remove debris. Cells were then detached from culture plates using cell 
scrapers and pelleted by centrifugation at 1300 rpm, for 3 minutes. Cell pellets were 
resuspended in 1x PBS and respective primary antibody was added (table 3). Cells 
were stained with primary antibody for 1 hour, on ice. Samples were then washed by 
centrifugation with 1x PBS. After washing, samples were resuspended in 1x PBS and 
respective secondary antibody for 30 minutes, on ice and protected from light. 
Finally, the cells were washed by centrifugation and resuspended in 200 µl 1x PBS, 
measured by FACS calibur and analyzed using FlowJo software. 
Apoptosis assay was performed to find the apoptotic rate of cells under the different 
culture conditions. Apoptosis assay was performed on monocytes and not 
macrophages. Apoptosis was measured by staining with Annexin V antibody. 5 x 105 
monocytes were seeded in a 25 cm3 culture flask. On experiment day, cells were 
pelleted by centrifugation at 1300 rpm, for 3 minutes. Pellets were resuspended in 
100 µl of freshly made 1x binding buffer (diluted from the stock of 10 x binding buffer: 
0.1 M HEPES, pH7.4, 1.4 M NaCl, 25 mM CaCl2). Cells were once again pelleted by 
centrifugation. Supernatant was discarded and pellet was resuspended in 100 µl 1x 
binding buffer containing 2.5 µl Annexin V antibody, per sample. Incubation with 
primary antibody was carried out for 15 minutes at room temperature. Cells were 
then washed in 1x binding buffer, by centrifugation as described above. Cells were 
resuspended in 100 µl 1x binding buffer containing 1:500 PE-streptavidin, per sample 
for 30 minutes on ice, protected from light. Cells were washed in 1x binding buffer, by 
centrifugation as described above and fluorescence intensity was measured by Flow 
cytometry and data was analyzed by FlowJo software.  
Table 3: Antibody list for Flow cytometry analysis 
Experiment Primary antibody (concentration) Secondary antibody 
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(corresponding result 
section) 
(concentration) 
Neu5Gc incorporation polyclonal chicken anti-Neu5Gc (1:500); 
Biotin anti-chicken (5 µg/ml) 
PE streptavidin 
   
cis-bound SIGLEC3 
detection 
mouse anti-SIGLEC3, clone WM53 (5 
µg/ml) 
mouse anti-SIGLEC3, clone HIM3-4 (5 
µg/ml) 
PE anti-mouse 
   
Apoptosis assay biotinylated anti-Annexin V (1:50) PE streptavidin 
 
2.2.10 Western Blot 
1 x 106 cells were seeded per well of a 6-well plate, per cell line (WT and SIG3 KO). 
Cells were treated as described in table 2. On the day of experimentation, cells were 
detached using cell scraper and pelleted by centrifugation. Each pellet was 
resuspended in 100 µl RIPA buffer containing 2 µl HALT proteases and 
phosphatases cocktail. Samples were incubated on ice for 1 hour and cellular debris 
was removed by centrifugation at 12000 rpm, for 15 minutes. Supernatant containing 
whole cell lysate was used to immunoprecipitate specific proteins for further analysis 
as described in table 4. Proteins were immunoprecipitated using either protein A or 
protein G dynabeads (ThermoFischer), per manufacturer’s protocol. After 
immunoprecipitation of the protein-of-interest, LDS loading buffer was added to the 
samples and heated for 10 minutes at 75 °C. Samples were directly loaded from the 
heating block, onto 10 % BIS-TRIS SDS PAGE and run in standard MES running 
buffer at 130 volts for 1.5 hours. Proteins were then transferred from the gel onto 
activated nitrocellulose blots in transfer buffer (40 ml 20x-NuPAGE transfer buffer 
diluted in 80 ml methanol and 680 ml ddH2O) for 1 hour at 380 mA. Blots were then 
blocked for 1 hour in TBST and stained overnight with first primary antibody diluted in 
TBST, at 4 °C (table 4). After overnight incubation, blots were washed three times for 
a total of 15 minutes in TBST. Blots were then incubated with respective secondary 
antibody (1:10,000) for 1 hour at room temperature followed by washing in TBST as 
described above (table 4). In some cases, a tertiary antibody was required – as 
described in table 4 – for which the stained procedure was carried out similar to that 
of the secondary antibody. After incubation with HRP-coupled antibody, the blots 
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were visualized using Super Signal Pico kit, per manufacturer’s protocol. Bands were 
detected using BioRad ChemiDoc XRS+ Molecular Imager and analyzed by 
ImageLab software. Blots were then striped off antibodies by rotating in striping buffer 
for 30 minutes at room temperature, washed for 15 minutes and blocked for 1 hour, 
in TBST. Following blocking, blots were stained in second primary antibody, as 
described in table 4. In general, the second primary antibody was the same as the 
antibody used for immunoprecipitation. This procedure was performed to normalize 
the first protein that was stained for, due to the lack of housekeeping protein for 
normalization. Secondary antibody staining, and if necessary tertiary antibody 
staining, was performed as described above.  
Table 4: Antibody list for Western blot analysis 
Experiment 
(corresponding 
result section) 
Antibody for 
immunoprecipitation 
(concentration) 
1st and 2nd primary 
antibody 
(concentration) 
secondary and 
tertiary antibody 
(concentration) 
SHP1 recruitment 
to SIGLEC3 
mouse anti-SIGLEC 3, 
clone HIM3-4 (5 µg/ml) 
mouse anti-SHP1 (2.5 
µg/ml) 
 
mouse anti-SIGLEC3, 
clone HIM3-4 (1 µg/ml) 
2ry ab: biotin anti-
mouse (1 µg/ml); 
 
3ry ab: HRP 
streptavidin  
(1 µg/ml) 
    
phosphoERK 
detection 
Total ERK (1:500) phosphoERK (1:1000) 
 
TotalERK (1:1000) 
HRP anti-rabbit  
(1 µg/ml) 
 
2.2.11 ROS production analysis by DHE staining 
Production of reactive oxygen species (ROS) was measured by DHE incorporation 
and detected using Flow cytometry. WT and SIG3 KO cells were seeded at a density 
of 70,000 cells per chamber onto 4 chambers of a chamber slide, per cell line. On 
day of experimentation, all chambers were treated with DHE (1:1000) in KREBS-
HEPES buffer for 15 minutes, protected from light. Cells were then immediately 
washed twice with 1x PBS and fixed using 4 % PFA and mouted with Mowiol-488. 
Slides were stored at 4 °C and imaged within 24 hours of staining by confocal 
microscopy. Triplicate images were taken per condition and analyzed using ImageJ 
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software. Area and integrated density of each image was measured, as well as mean 
fluorescence intensity of background. Normalized fluorescence intensity per image 
was calculated as follows: 
Area * Mean fluorescence intensity (background) – integrated density 
Values obtained were normalized to the WT SDm untreated condition for each 
experiment. Data was obtained in collaboration with and is described in the Master 
thesis of Omar Mossad. 
2.2.12 Phagocytosis assay 
Phagocytic capacity of cells was analyzed by the intake of fluorescently labeled 
biotinylated Aβ. Macrophages were seeded at a density of 70,000 cells per well on 4-
well chamber slides. After culture of macrophages under the respective conditions, 
cells were treated with biotinylated fibril Aβ for 1.5 hours at 37°C. After incubation, 
cells were gently washed twice with sterile 1x PBS and fixed for 10 minutes with 4 % 
PFA. After fixing, cells were washed with 1x PBS and blocked in 10 % BSA 
containing 5 % NGS and 0.1 % Triton-X-100. Cells were then stained with primary 
antibody against CD11b (rat anti-human CD11b, 5 µg/ml), overnight at 4 °C. On the 
next day, cells were washed twice with 1x PBS and incubated in secondary antibody 
Alexa fluor-488 anti-rat (1:500) and Cy3-streptavidin (1:500) for 90 minutes at room 
temperature, protected from light. Cells were washed twice with 1x PBS and mounted 
using Mowiol 488. Slides were stored at 4 °C till imaging. Imaging was performed 
using Confocal microscopy. Five images were taken per condition and analyzed 
using ImageJ software. Total number of cells and the number of cells with 
internalized Aβ were counted. Phagocytic rate was calculated as a ratio of phagocytic 
cells normalized to the total cell number per image.  
2.2.13 Real time PCR  
Gene transcription of complement component 3 (c3) and complement component 1q 
(c1q), was analyzed by real-time PCR. 5 x 105 cells were seeded per well of a 6-well 
plate. One well was seeded per condition and per cell line as described in table 2. On 
day of experimentation, cells were detached by scraping and pelleted by 
centrifugation at 1300 rpm, for 3 minutes. The pellets were then resuspended in 1 ml 
Qiazol and RNA was isolated by the classical chloroform-phenol technique. Isolated 
RNA was transcribed into cDNA by Superscript reverse transcriptase III. The 
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obtained cDNA was measured for impurities by 230/260 and 280/260 values using 
Nanodrop 1000. 100 ng of cDNA, per sample, was run as triplicates with respective 
primers (table 5), SYBRgreen and at annealing temperature 60 °C, to obtain Ct 
values. Obtained values were calculated using the standard ΔΔCt method. All values 
were normalized to the housekeeping gene gapdh. Data was obtained in 
collaboration with and is described in the Master thesis of Omar Mossad. 
Table 5: Antibody list for Western blot analysis 
gene  forward sequence reverse sequence 
c1q GCCCCGCAGTGGCAAGTTCA ACCTTCTGTGCACGCTCCCG 
   
c3 GAGGTCATAGTGGAGCCTACA GGTTAGAGACTGCACAGTGTC 
   
gapdh CTGCACCACCAACTGCTTAG TTCAGCTCAGGGATGACCTT 
 
2.2.14 Statistics 
All experiments were repeated at least 3 times and obtained data was checked for 
statistically significant differences using SPSS software by ANOVA test with 
Bonferroni correction. Significance was illustrated as * (p ≤ 0.05), ** (p ≤ 0.01), *** (p 
≤ 0.001) and n.s (not significant). 
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3. Results 
3.1 Developing human microglia from iPS cells as an in vitro 
model to study SIGLEC3 
The study of human microglia under healthy as well as pathological conditions 
requires a stable supply of microglia for functional and biochemical analysis. 
Limitations in number of primary microglia and abnormal alterations in primary 
microglial cell lines obtained by viral transduction hinder these analyses. Therefore, a 
differentiation protocol to obtain microglial cell lines from iPS cells was performed 
based on the protocol from Beutner and colleagues (Beutner et al. 2010), which 
describes differentiation of mouse microglial lines from mouse embryonic stem cells. 
A healthy iPS cell line, JS-AF12 was used to obtain Stem cell-derived microglial 
(SdMic) lines 1 and 2 (SdMic 1 and SdMic 2), which represent microglia in healthy 
individuals. The differentiation procedure of SdMic lines was performed as described 
in the Doctoral thesis of Dr. Kristin Roy (Roy 2012). 
The derived SdMic lines proved to be genetically instable. The instability of these 
lines was confirmed by increased chromosomal numbers in SdMic1 and SdMic2 in 
comparison to the JA-AF12 iPS cells from which they were generated (figure 7A). 
While the iPS cell line carried on average 46 chromosomes (46 ± 2.5) as expected 
for human material, microglial lines SdMic1 and SdMic2 carried 55 ± 2.3 and 53 ± 2.8 
chromosomes, respectively. Furthermore, SNP analysis of both microglial lines 
showed erroneous results as seen in figure 7B, in comparison to the iPS line JS-
AF12 from which they were generated. 
Therefore, an attempt to develop genetically stable and reproducible microglial cells 
was made in the scope of this thesis and is described below.  
Contrary to the previously described protocol, iPS cells (JS-AF 12) were cultured on 
a basement membrane matrix; namely Geltrex. All steps of the differentiation protocol 
are illustrated in figure 7C. The stem cells, cultured in TESR-E8 medium, formed 
colonies (figure 7C-1). The EBs formed were between 200 and 300 µM in size 
(figure7C-2) and were a combination of ectodermal, endodermal and mesodermal 
tissue as described in literature (schematic image, figure 7C-3). On the final day of  
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Figure 7: Previously generated SdMic lines 1 and 2 carry an increased number of 
chromosomes in comparison to the expected 46 chromosomes as seen in human material. While 
the JS-AF iPS from which SdMic1 and SdMic2 were generated carried 46 ± 2.5 chromosomes on 
average, SdMic1 and SdMic2 lines carried 55 ± 2.3 and 53 ± 2.8 chromosomes, respectively (A). 
Additionally, both SdMic lines have disrupted single nucleotide polymorphism (SNP) profile (B). 
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Modified protocol to obtain proliferative induced pluripotent stem cell derived microglia (iPSdM) 
(C) includes culturing of stem cells on a matrix-layer (C, 1) and developing embryoid bodies (C, 
2), consisting of all three germ layers (representative image C,3) that are double positive for KDR 
and CD235a, as seen by immunocytochemical staining (C, 4; representative image of at least 3 
independent experiments) and flow cytometry analysis (C, 5). On average, 21.6 % ± 0.5 % of EBs 
were positively co-stained for KDR and CD235a (C, 5). Development of neural and myeloid 
progenitors out of the EBs was supported (C, 6) and further differentiation into final cell types was 
initiated (C, 7). The differentiated microglia were positive for marker CD11b and were found 
among β-III-tubulin and neurofilament positive neural cell types. When rotated on the x-axis, a 
phagocytic microglia with internalized β-III-tubulin particles can be observed. 
suspension culture, the EBs were analyzed for the expression of KDR and C235a 
positive cells. Immunocytochemical analysis revealed co-localization of KDR and 
CD235a staining. Flow cytometry analysis revealed that KDR+CD235a+ double 
positive cells made up around 21.6 % ± 0.5 % of the total population, in comparison 
to isotype control; 0.5 % ± 0.0 % (figure 7C-5). The presence of double positive cells 
is indicative of primitive hematopoeisis, from which microglial cells arise. The 
absence of KDR+CD235a- cells indicated the absence of definitive hematopoeisis, 
from which peripheral macrophages and monocytes arise. EBs were then plated and 
directed to differentiate into neural and myeloid progenitor cell types (figure7C-6). 
The culture medium was switched to N2 medium supplemented with laminin and 
growth factor - rhFGF2. At this stage, the neural precursors were supported to 
develop into neural cell types and the myeloid precursors were supported to develop 
into primitive microglial cells (figure 7C-7). In the final stage of differentiation, cells 
were cultured in N2 medium in the absence of growth factors to support spontaneous 
differentiation of precursors into final cell types; microglial cells develop among other 
neural cell types (β III tubulin+; neurofilament+, figure 7C-7). Differentiation of 
microglia can develop at time points of up to 4 months after the initiation of 
differentiation. Microglial cells in the differentiation culture plates were 
morphologically identified as round-shiny cells of about 30 - 40 µm. The CD11b-
positive microglial cells develop alongside β III tubulin-positive neural cell types. In 
fact, preliminary indications of the phagocytic capacity of the microglial cells were 
observed by the presence of red-labeled β III tubulin elements within the green-
labeled microglia - as seen by z-stack analysis using confocal microscopy, when the 
image is rotated on its x-axis (figure 7C-8). The disadvantageous factor in the 
differentiation protocol was the limited number of microglial cells that developed per 
39 
 
EB. A rough estimate of a few thousand microglial cells per EB can be assumed. This 
disadvantage limits the extent of molecular analysis that can be performed. 
Nevertheless, increased microglial cell numbers possibly might be obtained by up-
scaling the EB seeding procedure. 
3.2 Characterizing microglial cells obtained from human iPS 
cells   
The generated microglial cells were named as induced pluripotent stem cell derived 
microglial cells 9 (iPSdM9). The microglial cells iPSdM9 were characterized based on 
proliferation rate and expression of typical microglial surface markers. Due to the 
limited cell numbers, the characterizations were performed in 96-well optical bottom 
plates as described in the materials and methods (sections 2.2.3 and 2.2.4). 
3.2.1 Immunocytochemical analysis 
Mechanically isolated microglial cells were positively stained for typical microglial 
markers such as CD11b, ionized calcium-binding adapter molecule-1 (IBA-1) and 
TREM2 (figure 8). The percentage of positive cells for each marker was calculated of 
the total number of cells from up to 7 individual images. Of the total cells, 36.84 % 
were positive for CD11b; 47.67 % were positive for marker IBA-1 and 54.55 % were 
positively stained for TREM2 (figure 8). Total number of cells per image was 
calculated from the number of nuclei identified by DAPI staining.  
3.2.2 Proliferative capacity 
The proliferative capacity of the cells was observed by Ki67 incorporation as seen by 
immunocytochemical staining and analyzed by confocal microscopy. Preliminary data 
shows that CD11b positive cells can incorporate Ki67, which indicates their ability to 
proliferate. However, detailed analysis of their proliferation rates need to be 
analyzed.  
In conclusion, the iPSdM9 cells could serve as a well represented alternative to 
primary human microglia, although cell number is very limited. The cells express 
typical microglial surface markers and preliminary data indicates that these cells are 
capable of phagocytosis and proliferation. However, further characterization of the 
cells is required. While the proliferative capacity of the cells would allow for in vitro 
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expansion, the number of cells obtained was insufficient for analyses of SIGLEC3 by 
molecular techniques as required by this project.  
 
Figure 8: iPSdM9 express microglial markers and are proliferative. The iPS 
derived microglia (iPSdM9) positively stain for typical microglial markers CD11b, IBA-1 and 
TREM2 (A). In addition, iPSdM9 incorporate Ki67 in their nuclei, which is an indication of the 
proliferative capacity of the cells (B). Cells were identified in all images by nuclei staining by 
DAPI.  
3.3 THP1 macrophages as human in vitro model to study 
SIGLEC3 
As discussed above, appropriate representative cell lines for primary human 
microglia are unavailable in sufficient numbers for functional and biochemical 
analysis. Due to this restriction, the currently most widely used human macrophage 
cell line was chosen as a human in vitro model to study SIGLEC3 and its signaling. 
Although microglia and macrophages develop from different phases of 
hematopoiesis, the final cell types show substantial overlap in terms of surface maker 
expression profile and functional capabilities. For all intents and purposes, the THP1 
monocyte-derived macrophage cell line possesses very similar functional 
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characteristics typical for phagocytes including the expression of functional human 
SIGLEC3. As previously stated, the protein of interest in this project is SIGLEC3. 
Therefore, particular focus was placed on deciphering whether the influence of 
incorporated sialic acids was mediated through SIGLEC3. For this purpose, all 
following experiments were performed on both wildtype (WT) THP1 cells as well as 
on SIGLEC3 knockout (SIG3 KO) THP1 cells.  
Collaborators at the research group of Prof. Dr. Hornung used crispr-cas9 to cause a 
4 base pair deletion from position 566 to 569 of the SIGLEC3 gene sequence (figure 
9A). The deleted region lies in exon 3 of the SIGLEC3 coding sequence and results 
in the absence of functional SIGLEC3 on the cell surface (figure 9B). Flow cytometry 
analysis with antibody against SIGLEC3 (clone WM53) shows a reduction of 
SIGLEC3 surface expression from 45.4 % to 0 % (subtracted from control antibody 
staining), as seen in example figure 9B (add figure). 
 
Figure 9: SIG3 KO cells carry a 4 base pair deletion rendering SIGLEC3 protein 
non functional. Collaborators from the group of Prof. Dr. Hornung (university of Bonn) 
successfully introduced a 4 base pair deletion in exon 3 of the SIGLEC3 gene using crispr-cas9 
technology into THP1 cells. The deletion ranges from base pair 566 to base pair 569, marked as 
hyphens in comparison to SIGLEC3 control sequence obtained from NCBI (ref seq. 
NM_001772.3) and aligned using GENtle software (A). Consequently, staining with SIGLEC3 
antibody in SIG3 KO THP1 cells confirmed the absence of the protein in comparison to WT THP1 
cells. Control antibodies determine unspecific staining (B).3.4 Effects of human sialic acid 
(Neu5Ac) versus non-human sialic acid (Neu5Gc) incorporation into cell surface 
glycocaylx 
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3.4 Influence of sialic acids on functions of THP1 
macrophages 
3.4.1 Incorporation of Neu5Ac and Neu5Gc into the cellular glycocalyx of THP1 
macrophages 
As described under the methods section, experiments were performed on THP1 cells 
cultured in either Neu5Ac containing-medium (ACm) or Neu5Gc-containing medium 
(GCm). As control, cells were cultured in medium lacking additional sialic acids - 
named as sialic acid depleted medium (SDm). THP1 macrophage cells were cultured 
in GCm to mimic the cellular and molecular environment in which non-human sialic 
acids, metabolically incorporated through consumption of red meat and milk 
products, could accumulate and consequently affect SIGLEC3 function. 
First, incorporation of Neu5Gc into the cell surface glycocalyx of THP1 macrophages 
was analysed. The macrophages cultured in either ACm or GCm incorporated either 
Neu5Ac alone or a combination of Neu5Ac and Neu5Gc, respectively. These results 
were obtained by flow cytometry analysis and xCGE-LIF technique, as described 
below. 
Flow cytometry analysis of Neu5Gc. THP1 WT as well as SIG3 KO cells cultured 
in GCm were positively stained for Neu5Gc (16.4 % ± 0.85 %). On the other hand, 
when both cell lines were cultured exclusively in ACm, no Neu5Gc staining was 
visible (2.1 %) in comparison to secondary antibody controls (1.5 %, representative 
image in figure 10A). Chronic exposure to fibrillary Alzheimer disease associated 
amyloid- β (Aβ) to cells significantly increased the appearance of Neu5Gc on the cell 
surface for both WT and SIG3 KO cells to 39.7 % ± 1.5 % and 24.9 % ± 1.3 % 
respectively, in comparison to untreated WT and SIG3 KO cells at 16.0 % ± 0.9 % 
and 12.7 % ± 1.7 %, respectively (figure 10B).  
The comparable expression of Neu5Gc in both WT and SIG3 KO in untreated cells 
indicates that SIGLEC3 does not influence the uptake and incorporation of this 
glycan. However, Neu5Gc staining significantly increased when both cell types was 
chronically exposed to low concentrations of Aβ. While SIG3 KO cells chronically 
treated with Aβ tended to incorporate lower levels of Neu5Gc, the difference was 
insignificant compared to WT cells chronically treated with Aβ. 
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XCGE-LIF analysis. While flow cytometry data detects total Neu5Gc on the cell 
surface, a second technique – xCGE-LIF was performed to identify the presence of 
Neu5Gc incorporated exclusively in total proteins. Collaborators from the group of Dr. 
Erdmann Rapp (MPI-DCTS, Magdeburg) confirmed the above mentioned flow 
cytometry results using the advanced xCGE-LIF technique (representative image, 
figure 10C). Total proteins extracted from cells cultured in either ACm or GCm were 
analyzed for the presence of Neu5Ac or Neu5Gc sugars. The former expressed 100 
% ± 0.0 % Neu5Ac while the latter sample carried 1.2 % ± 0.0 % of Neu5Gc and 98.8 
% ± 0.0 % of Neu5Ac sugars, (figure 10D).  
Therefore, it can be concluded that Neu5Gc is effectively taken up by the 
macrophages and expressed on the cell surface. Neu5Gc found on the cell-surface 
glycocalyx can be available as a ligand for sialic-acid binding receptors. The 
discrepancies in the percentages of Neu5Gc expression between flow cytometry data 
and xCGE-LIF data can be explained by the fact that exclusively protein-bound 
Neu5Gc is measured in the latter case. Therefore it is vital to repeat the xCGE-LIF 
analysis to detect Neu5Gc on total lipid content to obtain overall quantities. 
Nevertheless, despite modest percentages of Neu5Gc incorporation, it is sufficient to 
cause disruption in several cellular processes as seen by RNA sequencing analysis 
described in section 3.4.2. 
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Figure 10: Neu5Gc can incorporate in cells cultured in GCm. Flow cytometry 
analysis for Neu5Gc detection was performed using a specific chicken polyclonal antibody. 
Neu5Gc was positively stained in GCm cells but not ACm cells. Control antibody determines 
unspecific staining (A; representative image of at least 3 independent experiments). Both WT and 
SIG3 KO effectively incorporated Neu5GC at 16.0 % ± 0.9 % and 12.7 % ± 1.7 %, respectively. In 
both cell lines, chronic treatment with Aβ significantly increased Neu5Gc incorporation to 39.7 % 
± 1.5 % and 24.9 % ± 1.3 %, respectively (B). Detailed analysis exclusively on glycoproteins 
using xCGE-LIF technique confirmed Neu5Gc incorporation in GCm and not ACm cultured cells 
(C; representative image of at least 3 independent experiments). Measurement by xCGE-LIF of 
cultured cells from three independent experiments was quantified (D). n=3.  
3.4.2 Incorporated Neu5Gc causes broad cellular dysregulation 
In collaboration with the group of Prof. Dr. Schultze (LIMES, Bonn) used RNA 
sequencing for an in-depth analysis of the influence of Neu5Ac and Neu5Gc 
incorporation. RNA sequencing analyses revealed that SDm cultured control cells 
clustered closely with ACm cultured cells, while GCm cultured cells showed several 
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differentially expressed genes (figure 11A). Of the differentially expressed genes, a 
total of 768 genes were up-regulated and a total of 707 genes were down-regulated 
in GCm cells compared to a combination of ACm and SDm cells. On the other hand, 
only 60 and 39 genes were up- and down-regulated in ACm compared to SDm, 
respectively. The genes listed were of fold change 1.5 and higher. Particularly, proto-
oncogene candidate BLC3 and regulator of cell growth and division EP300 were up-
regulated in GCm cells. Furthermore, GO enrichment analysis highlighted several 
pathways, such as cellular signaling, regulation of immune responses, immune cell 
development and responses to stimuli, which were altered in GCm cells compared to 
ACm cells (figure 11B).  
Therefore, incorporation of immunogenic Neu5Gc disrupts cellular processes on a 
wide scale leading to a dysfunctional cellular signaling and immune response from 
the cells. 
3.4.3 Incorporated sialic acids can bind SIGLEC3 and chronic treatment with 
Aβ increases binding to SIGLEC3 
To elucidate the binding capacity of SIGLEC3 to both Neu5Ac and Neu5Gc sugars, 
SIGLEC3 Fc-fusion protein binding was measured by flow cytometry. Wildtype THP1  
 
Figure 11: Neu5Gc incorporation causes wide-spread cellular dysregulation. 
Heat map analysis of differentially expressed genes shows that ACm clusters to control - SDm, 
while GCm cultured cells cluster away (A). Gene ontology enrichment analysis highlights several 
pathways, including cellular signaling, regulation of immune responses, immune cell development 
and responses to stimuli, which are dysregulated in GCm cultured cells compared to ACm 
cultured cells (B). n=3. 
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monocyte-derived macrophages cultured under ACm or GCm bound SIGLEC3 Fc-
fusion protein to the same extent (56.8 % ± 2.7 % and 62.5 % ± 4.4 %, respectively). 
The percentage of binding was significantly increased in cells that were chronically 
exposed to Aβ, irrespective of the type of sialic acid incorporated (75.0 % ± 0.4 % 
and 72.1 % ± 2.4 %, respectively) (figure 12A). Therefore, the data obtained confirms 
that both incorporated sialic acids, Neu5Ac as well as Neu5Gc, can bind to SIGLEC3 
Fc-fusion protein. Additionally, the increase in SIGLEC3 Fc-fusion protein binding 
under chronic exposure to Aβ correlates well with the increased expression of its 
ligand, namely, sialic acids as seen above (section 3.3.1; figure 10B).  
SIGLEC3 expression: ligand-bound protein versus total protein. Like other 
members of the SIGLEC family, SIGLEC3 can constitutively interact with cis-bound 
sialic acids. From literature, it is known that a small percentage of SIGLEC3 
receptors are bound in cis, to self-ligands, to maintain a baseline homeostatic 
inhibitory signal. Using two SIGLEC3 antibody clones with different binding epitopes, 
the percentage of cis-bound SIGLEC3 was determined. Clone WM53 binds to a 
unique epitope on the protein, which is independent of ligand binding, therefore total 
protein expression, can be elucidated. A second available clone; HIM3-4 binds an 
epitope close to the ligand-binding epitope of the protein.  
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Figure 12: SIGLEC3 binds Neu5Gc in cis to a higher degree than Neu5Ac.  
SIGLEC3 can bind to both Neu5Ac (56.8 % ± 2.7 %) and Neu5Gc (62.5 % ± 4.4 %). Under both 
culture conditions, chronic treatment with Aβ increases SIGLEC3 Fc-fusion protein binding to 
75.0 % ± 0.4 % and 72.1 % ± 2.4 %, respectively (A). Of the total SIGLEC3 expressed on the cell 
surface, roughly half are expected to be ligand-bound to maintain baseline homeostatic inhibitory 
signaling (representative image, B). The difference between total protein expression of SIGLEC3 
(determined by clone WM53 antibody binding) and SIGLEC3 free from ligand-binding 
(determined by clone HIM3-4 antibody binding) provides the % of SIGLEC3 cis-bound to ligands 
(C). A ratio of the bound SIGLEC3 to total SIGLEC3 indicates that GCm cultured cells 
constitutively bind SIGLEC3 to a higher degree than SDm and ACm cultured cells. Similarly, cells 
chronically treated with Aβ bind SIGLEC3 to a higher degree than untreated cells, irrespective of 
culture conditions (C; average ± SEM). n=4 
Therefore, binding of the HIM3-4 clone would only occur if the protein is free from 
ligand binding (figure 12B). By calculating the difference between the total SIGLEC3 
(% of WM53 binding) and the free SIGLEC3 (% of HIM3-4 binding), it is possible to 
identify the percentage of protein bound by ligands (figure 12C). By this logic, it was 
identified that approximately half of total SIGLEC3 protein expressed is bound in cis 
with self-ligands (cis-bound/total protein; 0.45 ± 0.06 and 0.45 ± 0.05 under SDm and 
ACm culture, respectively). Interestingly, cells cultured in GCm showed significantly 
higher cis-interacting SIGLEC3 (0.78 ± 0.09). Similarly, chronic stimulation of cells 
with low dosages of Aβ also significantly increased SIGLEC3 cis-binding in SDm and 
ACm culture (0.79 ± 0.07 and 0.73 ± 0.04, respectively). However, chronic treatment 
with Aβ under GCm did not further increase the already higher percentage of cis-
bound SIGLEC3 (0.72 ± 0.07, figure 11B). In conclusion, around half of the SIGLEC3 
expressed is cis-bound to maintain homeostatic inhibition. Additionally, Neu5Gc 
elicits a comparable increase in cis-bound SIGLEC3 (figure 12C).  
In the case of Neu5Gc, its ability to incorporate into the cellular glycocalyx (figure 10) 
as well as its binding capacity to SIGLEC3 has been confirmed (figure 12A), as 
described above. In addition to this, there is significantly more binding to SIGLEC3 as 
compared to ACm and SDm cultures (figure 12B). However, since Neu5Gc is a 
foreign sialic acid to the human SIGLEC3, the question remains: does binding of 
Neu5Gc to SIGLEC3 propagate inhibitory signaling? 
3.4.4 Neu5Gc bound to inhibitory receptor SIGLEC3 does not propagate 
inhibitory signaling 
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Western blot analysis revealed reduced recruitment of downstream molecules of the 
inhibitory pathway, which indicate absence of inhibitory signaling, under GCm culture 
conditions.  
Direct evidence for the absence of inhibitory signaling can be elucidated from the 
shp1 recruitment to SIGLEC3. SIGLEC3, upon ligand binding, recruits shp1 to further 
propagate inhibitory signaling. Insufficient shp1 recruitment could be indicative of 
inadequate SIGLEC3 ligand binding. The efficiency of shp1 recruitment to SIGLEC3 
can be measured by co-immunoprecipitation of both proteins (representative image, 
figure 13A). Under ACm culture, shp1 could be successfully detected on 
immunoprecipitated SIGLEC3. While there is only a tendency towards a decrease in 
shp1 recruitment upon chronic treatment with Aβ, GCm cultured cells recruited 
significantly less shp1 than ACm cultured cells (figure 13B). The significantly lower 
amounts of shp1 recruited to SIGLEC3 in GCm cultured cells indicate that Neu5Gc 
binding to SIGLEC3 does not adequately activate SIGLEC3 signaling. Whether the 
inadequate binding is due to steric hindrance or conformational changes on the side 
of the protein or ligand, is yet to be determined. Nevertheless, it can be concluded 
that while Neu5Gc can incorporate into the cell surface glycocayx as well as bind 
SIGLEC3, the SIGLEC3 inhibitory signaling is not effectively propagated. The 
absence of signaling by an important homeostatic inhibitory receptor such SIGLEC3 
could be hypothesized to cause chronic activation of the cells. 
 
Figure 13: Reduced shp1 recruitment to Neu5Gc-bound SIGLEC3. SHP1 
recruitment to SIGLEC3 was obtained by measuring SHP1 antibody stained bands normalized to 
SIGLEC3 antibody stained bands (A representative image of 4 independent experiments). 
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Inhibitory signaling through SIGLEC3 is propagated through shp1 recruitment as seen in ACm 
cultured cells. In comparison, GCm cultured cells recruit significantly less shp1 as seen by 
western blot analysis. Chronic treatment with Aβ did not influence shp1 recruitment under either 
culture condition (B). n=4. 
3.4.5 SIGLEC3 knockout but not Neu5Gc incorporation during chronic 
exposure to Aβ downregulates cellular metabolism 
MTT analysis revealed that neither the type of sialic acid nor chronic exposure to low 
concentrations of Aβ affected the metabolic rate. However, the loss of SIGLEC3 
signaling significantly reduced cellular metabolism, irrespective of the sialic acid 
feeding or the Aβ treatment (figure 14). To further elucidate the metabolic status of 
the cells between the two cell types and under the different conditions, the apoptotic 
rate was also analyzed by flow cytometry, as described below (section 4.3.6). 
3.4.6 Neu5Gc incorporation but not SIG3 KO induces apoptosis 
Apoptosis assay was performed to determine whether Neu5Gc incorporation of 
chronic treatment with Aβ induces programmed cell death. Apoptotic rate of cells was 
measured by Annexin V staining, using flow cytometry. Annexin V binds 
phosphatidylserine which is exposed on the cell surface of apoptotic cells.  
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Figure 14: Reduced cellular metabolic activity in SIG3 KO cells. All culture 
conditions and treatment were comparable within each cell line. Significant 
differences were only seen between wildtype untreated cells and its corresponding 
SIG3 KO sample. These differences remained insignificant in the case of chronic Aβ 
treatment in all cultured conditions n=3.   
Therefore, the percentage of apoptosis can be elucidated from the percentage of 
Annexin V staining. Flow cytometry analysis revealed that GCm cultured cells were 
significantly more apoptotic than SDm and ACm cultured cells (figure 15). Chronic 
treatment with Aβ did not influence the apoptotic rate of the cells, irrespective of the 
culture conditions. In accordance with MTT analysis, SIG3 KO cells were significantly 
less apoptotic than WT cells under each corresponding culture condition. The 
lowered apoptotic rate correlates with the lowered metabolic rate of the SIG3 KO 
cells, in comparison to WT.  
 
Figure 15: Neu5Gc induces apoptosis. GCm cultured cells were significantly more 
apoptotic than SDm and ACm cultured cells. Chronic treatment with Aβ did not influence 
apoptosis. SIG3 KO cells were significantly less apoptotic in comparison to corresponding culture 
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condition in WT cells, except in SDm untreated cells. Apoptotic rate of SIG3 KO cells remained 
unchanged, irrespective of sialic-acid feeding and chronic treatment with Aβ. n=3. 
3.4.7 Neu5Gc in combination with Aβ treatment induces molecules of 
activatory pathways 
Indirect evidence of absent inhibitory signaling was obtained by detecting the 
phosphorylation status of the downstream activatory molecule ERK (extracellular 
signal regulated kinases) at 42 and 44 kDa, normalized to total ERK protein 
immunoprecipitated (figure 16A). Increase in phosphorylated ERK (pERK) in ratio to 
total ERK (tERK) indicates increased activation of the cells. THP1 WT cells cultured 
under GCm conditions showed a tendency towards increased phosphorylated ERK in 
comparison to ACm cells. However, the GCm induced increase was not significant. 
Similarly, chronic Aβ exposure in ACm cultured cells was also insufficient to induce 
significant phosphorylation of ERK. Interestingly, a combination of GCm culture and 
chronic Aβ exposure significantly up regulated the phosphorylation of ERK. This up 
regulation was comparable to the increased ERK phosphorylation seen in SIG3 KO 
cells under all culture conditions (figure 16B). 
3.4.8 Neu5Gc incorporation but not SIG3 KO or chronic treatment with Aβ 
causes radical bursts. 
Reactive oxygen species (ROS) production was analyzed to assess the radical 
production under the different sialic acid feeding conditions. SDm and ACm cultured 
cells produced comparable amounts of ROS, as measured by DHE staining. In 
comparison to SDm and ACm cells, GCm cultured cells produced significantly higher 
quantities of ROS. However, chronic Aβ exposure did not induce ROS production 
under any culture condition (figure 17).  
It is crucial to indicate that while cells chronically exposed to Aβ under SDm and 
ACm conditions are not in a pro-inflammatory status; phagocytosis could still be 
induced, as shown in the data below (section 4.3.9). In the case of SIG3 KO cells, 
absence of inhibitory signaling did not induce ROS production. SIG3 KO cells 
produced comparable quantities of ROS irrespective of the type of sialic acid feeding 
and chronic treatment with Aβ.  Therefore, Neu5Gc induced ROS production cannot 
be propagated in the absence of SIGLEC3. 
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Figure 16: Increased phosphorylated ERK in GCm cultures, only when 
chronically stimulated with Aβ. Western blot analysis shows significant increase in 
phosphorylation of activatory molecule ERK, normalized to total ERK for corresponding sample, 
in GCm cultured cells with chronic Aβ treatment. GCm culture or chronic Aβ culture alone did not 
elicit a significant increase in phosphorylated ERK. SIG3 KO cells also expressed significantly 
higher phosphorylated ERK in SDm and ACm compared to corresponding untreated WT 
cells.n=5. 
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Figure 17: Increased radical production in GCm cultured cells. Representative 
images of at least five independent experiments, for DHE staining (A). DHE staining analysis 
revealed an increase in ROS production in GCm cultured WT cells in comparison to SDm and 
ACm cultured WT cells. Chronic treatment with Aβ showed a slight but insignificant increase in 
ROS compared to corresponding untreated culture conditions. SIG3 KO remained unchanged, 
irrespective of culture condition and treatment (B). n= 5-7. 
3.4.9 Neu5Gc incorporation, loss of SIGLEC3 or chronic Aβ exposure influence 
phagocytic capacity of macrophages 
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Phagocytosis activity was analyzed by measuring the percentage of engulfed 
biotinylated Aβ (bAβ) after acute treatment. For acute stimulation to measure 
phagocytosis capacity, bAβ was used as opposed to non-biotinylated Aβ for technical 
reasons. Biotinylation site of bAβ can be fluorescently labeled with a streptavidin-
coupled secondary antibody for detection by confocal microscopy. Data obtained 
reveals a significant increase in phagocytic capacity of cells in GCm cultured 
compared to SDm and ACm cultured cells. Additionally, chronic treatment of the cells 
with Aβ also significantly increased phagocytosis compared to untreated samples 
under each culture condition (figure 18). 
 
Figure 18: GCm culture as well as chronic treatment with Aβ influence 
phagocytotic capacity of cells. Representation images of five independent experiments, 
imaged on x-, y- and z-axis (A). In WT cells, phagocytosis rate under SDm and ACm culture can 
be increased by chronic treatment with Aβ. GCm cultured cells constitutively phagocytose 
significantly higher amounts of biotinylated Aβ, compared to SDm and ACm untreated cultures. 
SIG3 KO cells constitutively phagocytose at a significantly higher rate, irrespective of sialic acid 
feeding or Aβ treatment, when compared to respective WT cells (B). n=5. 
 In combination with the ROS production analysis, it can be concluded that increased 
phagocytosis induced by chronic treatment with Aβ occurs in an anti-inflammatory 
manner, namely without radical bursts. On the other hand, increased phagocytosis 
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induced by culturing cells in Neu5Gc containing medium occurs in a pro-inflammatory 
manner, namely accompanied by radical bursts. SIG3 KO cells constitutively 
phagocytose significantly higher amounts, when acutely stimulated with Aβ, in 
comparison to WT cells cultured under the same conditions. Type of sialic acid 
culture as well as chronic treatment with low concentrations Aβ did not influence the 
phagocytic capacity of SIG3 KO cells.   
3.4.10 Neu5Gc induces transcription of complement cascade molecules 
Previous studies have identified an increased activity of classical complement 
cascade components in LAOD patients. Since induction of the classical complement 
cascade can modulate phagocytosis, gene transcription of components c1q and c3 
were analyzed to determine whether they correlate with the increased phagocytosis 
seen in GCm cultured cells (section 4.3.9). While gene transcription of c1q is 
exclusively found in the induction of classical complement cascade, transcription of 
c3 occurs in all complement cascades (classical, lectin and alternative complement 
cascades).  
Real time PCR analysis revealed increase in transcription of classical complement 
components exclusively in GCm cultured cells (figure 19). Both components only 
showed significant differences between ACm and Gcm cultured cells. GCm cultured 
WT cells transcribed significantly higher amounts of c1q and c3 than ACm cultured 
WT cells. On the other hand, SIG3 KO cells showed a tendency for reduced 
transcription of both factors in comparison to WT THP1 cells (figure 19). No 
significant differences in transcription were observed in SIG3 KO cells among the 
different culture conditions as well as treatments for c3 transcription (figure 19A). In 
the case of c1q transcription in SIG3 KO cells, while a tendency for increased 
transcription was observed after chronic treatment with Aβ, these differences were 
insignificant (figure 19B). 
Therefore, induction of complement cascade molecules correlate with increased 
phagocytosis seen in GCm cultured cells. To determine whether the increased 
phagocytosis in GCm cultured cells is indeed mediated through the classical 
complement pathway, inhibition studies using antibodies blocking complement 
receptor 3 (CR3) must be performed (preliminary data in section 4). While increased 
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phagocytosis in GCm cultured cells could be hypothesized to be mediated by the 
complement cascade, this is not the case for cells chronically treated with Aβ.  
 
 
Figure 19: GCm cultured cells significantly increase transcription of 
complement components. C1q and C3 are components of the classical 
complement cascade. Both components are significantly increased when cells are 
cultured in GCm, irrespective of chronic Aβ treatment. SIG3 KO cells tended to 
transcribe lower levels of both components, however the reduced transcription levels 
were not significant. (A) n=3-4; (B) n=3-5. 
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3.4.11 TREM2 expression is induced by chronic treatment with Aβ in WT cells 
and drastically reduced in SIG3 KO cells. 
Increased TREM2 expression has been previously observed in Aβ plaque-associated 
microglia in LOAD brains. One function of TREM2 signaling includes modulation of 
phagocytosis. Therefore, expression of TREM2 was studied as a possible 
mechanism by which phagocytic capacity of cells can be increased upon chronic 
treatment with Aβ, as seen in section 3.4.9. 
In WT cells cultured under SDm or ACm conditions, chronic treatment with Aβ 
significantly increases TREM2 expression. However, GCm cultured WT cells could 
not be induced to increase TREM2 protein expression, irrespective of chronic 
treatment with Aβ. Interestingly, SIG3 KO cells drastically reduced TREM2 
expression levels and neither culture conditions nor chronic treatment with Aβ could 
induce modulation of TREM2 expression.  
Therefore, increase in TREM2 expression correlates with increased phagocytosis 
seen in WT cells chronically treated with Aβ, under SDm and ACm cultures. To 
determine whether this increased phagocytosis is indeed mediated via TREM2 
signaling, inhibition studies using blocking antibody against TREM2 must be 
performed (preliminary data in section 4). While modulation of phagocytosis observed 
in WT cells could be hypothesized to be mediated via TREM2, the increased 
phagocytosis seen in SIG3 KO cells occurs despite significantly reduced TREM2 
expression levels. Therefore, the increased phagocytic activity of SIG3 KO cells is 
mediated by a unique pathway not including TREM2 signaling.   
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Figure 20: Trem2 protein expression is not inducible in GCm cultured cells and 
drastically reduced in SIG3 KO cells. TREM2 protein expression was inducible 
upon chronic treatment with Aβ, when WT cells were cultured in SDm or ACm 
conditions. However, GCm cultured WT cells were incapable of increasing TREM2 
expression, when chronically treated with Aβ. SIG3 KO cells significantly reduced 
TREM2 expression in comparison to WT in corresponding samples, irrespective of 
culture conditions or Aβ treatment. n=5. 
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4. Discussion 
Evolution of the modern man began with the first member of the genus Homo over 
2.5 million years ago. Over the numerous species ranging from Homo habilis to 
modern man, several crucial evolutionary changes occurred to ensure survival 
against external factors like climate and predators (Noonan 2010). In addition to 
physical changes in the skeletal and nervous system, vital changes in the immune 
system also occurred (Abi-Rached et al. 2011). Around 2 million years ago, one such 
crucial change occurred exclusively in members of the genus Homo at the molecular 
level, namely a 92 base pair deletion in exon 6 of the gene cmah (Chou et al. 
1998)(Varki 2001). The enzyme CMAH is responsible for hydrolyzing acetylated sialic 
acid (Neu5Ac) to produce glycosylated sialic acid (Neu5Gc). Taken together, the 
development of a complex CNS as well as a robust immune system led to a thriving 
species of humans that are continually evolving to this day. The immune system, 
including phagocytes such as macrophages in PNS and microglia in the CNS are 
crucial in defending the host against infections. Microglia in the CNS maintain 
homeostasis and therefore are vital in supporting co-ordinated functioning of the 
host.    
4.1 Functions of microglia and their contribution to LOAD 
4.1.1 Microglia in health and disease 
Microglia are the only resident immune cells of the immune-privileged CNS. Being 
the primary-response team to protect the CNS, microglia express specialized 
receptors that are useful in detecting chemical imbalances or changes indicative of 
various stimuli ranging from dangerous pathogenic invasion to routine synaptic 
pruning. In the case of the former, microglia are stimulated towards a pro-
inflammatory state. Pro-inflammatory status refers to the state at which microglia can 
effectively proliferate, migrate to site-of-infection and destroy invading pathogens by 
phagocytosis and radical bursts. Radicals such as reactive oxygen species (ROS) or 
reactive nitrogen species (RNS), among others, are a necessary by-product of pro-
inflammation upon stimuli with pathogen-associated molecular patterns (PAMPs). In 
addition to destroying pathogens, radical bursts also cause collateral damage to 
neighbouring host cells. However, production of radicals is often a fast and transient 
event and therefore collateral damage to host cells is highly localized and limited.  
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Besides host defense, maintenance of homeostasis by phagocytosing apoptotic cells 
and synaptic pruning are by far some of the most important responsibilities of 
microglia (Maderna & Godson 2003)(Tremblay et al. 2010). Synaptic pruning during 
development as well as in the adult CNS can be mediated by anti-inflammatory 
phagocytosis without radical damage to neighbouring cells (Michelucci et al. 
2009)(Paolicelli et al. 2011)(Bilimoria & Stevens 2015)(Wu et al. 2016). In addition, 
immune cells in this state can release neuroprotective factors such as BDNF, GDNF 
and TGFβ. Taken together, microglia perform numerous and complex functions, 
which are sensitively balanced in order to maintain homeostasis and provide immune 
defense.  
Therefore, an imbalance in the sensitive signaling of microglia can lead to a 
disproportionate response resulting in chronic inflammation and neurodegeneration 
(Bradshaw et al. 2013)(Brown & Neher 2014)(Bodea et al. 2014).  
In the case of AD, the most obvious pathological features found in post-mortem AD 
brains are extracellularly accumulated Aβ plaques and intracellularly accumulated tau 
proteins. However, studies show that AD patients with clinically diagnosed dementia 
as well as age-matched non-demented controls both have Aβ deposits (Coria et al. 
1993)(Esparza et al. 2014). The critical difference between AD patients and control 
individuals lie with the plaque morphology/density and their associated glial cells. 
Post-mortem studies show that an AD brain has a higher plaque coverage and 
severe microgliosis and astrogliosis proximal to plaques, in comparison to a non-
demented brain (Esparza et al. 2014). For this reason, the molecular environment in 
a pre-clinical AD brain must be intensively studied to identify the initial source of 
inflammation. Decades before cognitive deficits begin to manifest in an AD patient, 
molecular events occur, that distinguish a potential AD brain from non-demented 
control. One such event is the upregulation of the classical complement pathway 
(Hong et al. 2016)(reviewed by Tosto & Reitz 2013). This association is further 
substantiated by genome-wide association studies (GWAS) that have identified 
complement receptor 1 (CR1) as a risk factor for LOAD (Hollingworth et al. 
2011)(reviewed by Tosto & Reitz 2013).  
In addition, inflammation is also found in early stages of LOAD. Microglia are 
considered as one of the primary sources of inflammation in the CNS (Streit 
2004)(Ridolfi et al. 2013)(reviewed by Doens et al. 2014)(Malik et al. 2015).  
61 
 
4.1.2 Inflammation in LOAD 
Neuroinflammation is widely accepted as the cause leading to degeneration of 
neurons. Microgliosis has been found to be a pathological feature of AD, along with 
Aβ plaques (Solito & Sastre 2012)(Herber et al. 2007). However, studies which 
indicate that Aβ can induce inflammation should be critically viewed due to the 
technicalities behind the experimental setups. On the one hand, several studies load 
high quantities, above biological levels, of fibrillary Aβ to elicit a pro-inflammatory 
stimuli (Milton et al. 2008)(Parajuli et al. 2013). On the other hand, several studies 
use cellular or animal models that do not fully represent the array of human specific 
receptors or ligands (Milton et al. 2008)(Parajuli et al. 2013)(Chin 2011). Therefore, 
attention must be paid to the experimental setup as well as model system used to 
study the source of inflammation that exacerbates LOAD pathology.  
The typical microglial characteristic functions were studied in this thesis to elucidate 
the possible pathways that lead to pre-clinical inflammation. To fully understand the 
microenvironment of microglial cells, their receptors and ligands must be taken into 
account. One feature that is unique to human cells are their sialic acid composition.  
4.2 Sialic acids and SIGLECs  
A single sialic acid molecule, termed by the swedish biochemist Gunnar Blix in 1952 
(Blix et al. 1952), is a glycan monomer in its most basic form. Although small and 
seemingly irrelevant, sialic acids are vital molecules with several functions among all 
eukaryotes (Varki & Gagneux 2012)(Rachmilewitz 2010). Mammalian cells utilize the 
sialic acids in their multifarious combinations and conformations to communicate and 
maintain homeostasis. Studies have attributed reduced neurotoxicity by radicals and 
increased life span to sialic acids and their binding to receptors (Claude et al. 2013; 
Schwarz, Pearce, et al. 2015)(Schwarz, Springer, et al. 2015). This sensitive 
signaling through sialic acids has been hijacked by pathogens to evade host immune 
response upon infection by molecular mimicry (Doxey & McConkey 2013). Sialic 
acids and their receptors are perenially in an evolutionary race to overcome 
pathogen mimicry and improve upon host immune defence (Wang et al. 
2012)(Padler-Karavani, Tremoulet, et al. 2013). Protection against zoonotic diseases 
has been hypothesized as one of the main criteria for the loss of CMAH enzyme 
functionality specifically in humans (reviewed by Varki 2001).  
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The loss of Neu5Gc as a native ligand to human sialic-acid binding receptors led to a 
desensitization of these receptors to Neu5Gc and a preference towards Neu5Ac 
(Blixt et al. 2003)(Padler-Karavani, Hurtado-Ziola, et al. 2013). One such family of 
sialic acid binding receptors include SIGLECs. The majority of SIGLECs, called 
CD33-related SIGLECs, are rapidly evolving and differ from species to species. One 
clear example of species differences among CD33-related SIGLECs can be seen in 
the receptor SIGLEC3. Human SIGLEC3 (hSIGLEC3) carries two intracellular 
tyrosine-based inhibitory motifs. The tyrosine-based inhibitory motifs (ITIM and ITIM-
like), by which hSIGLEC3 signals, can propagate an inhibitory signaling cascade 
which modulates activatory signaling pathways. On the other hand, mouse SIGLEC3 
(mSIGLEC3) carries a single ITIM-like domain intracellularly and additionally carreis 
a positively charged residue in the transmembrane region. The positively charged 
residue is a putative association site for the activatory protein DAP12. Therefore, it 
can be assumed that mSIGLEC3 could propagate activatory signaling pathways 
(Crocker et al. 2007). This high variability in the family of SIGLECs among mammals 
hints at the sensitivity towards and complexity of their preferential ligands, namely 
sialic acids (Padler-Karavani et al. 2014). 
Although humans are incapable of producing Neu5Gc from Neu5Ac, several studies 
have shown trace evidence of Neu5Gc found in human cancer tissue and fetal tissue 
as well as antibodies against Neu5Gc in the blood stream (Malykh et al. 
2001)(Tangvoranuntakul et al. 2003)(Hedlund et al. 2007).  However, the non-human 
immunogenic sialic acid elicits an immune reaction in response to Neu5Gc, called 
xenosialitis (Bergfeld et al. 2012)(Samraj et al. 2015). Xenosialitis leads to 
inflammation and exacerbation of vascular pathology. 
The source of immunogenic Neu5Gc in human tissue was found to be metabolic 
incorporation from diet (Bardor et al. 2005)(figure 6). Once exposed on the cellular 
glycocalyx, sialic acids are available as ligands to sialic acid binding receptors. 
Futhermore, due to the desensitization of the human system to Neu5Gc, this sialic 
acid is rather resistent to enzymatic turnover by human sialidases, leading to an 
accumulation on cells when a persistent source is available (Taguchi et al. 
2015)(Davies et al. 2012). Therefore, Neu5Gc could be hypothesized to disrupt 
cellular homeostasis. This possibility is of interest with respect to LOAD for two 
reasons; first, Neu5Gc has been proven to elicit an immune response and therefore 
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cause inflammation (Samraj et al. 2015). Second, sialic acids including Neu5Ac and 
Neu5Gc are ligands to the inhibitory receptor SIGLEC3. Polymorphisms of SIGLEC3 
have been associated to LOAD by GWAS (Hollingworth et al. 2011). Furthermore, 
while xenosialitis has been implicated in cancer progression (Malykh et al. 
2001)(Samraj et al. 2015), autoimmune hypothyridism (Eleftheriou et al. 2014) and 
infertility (Ma et al. 2016), the inflammatory response to Neu5Gc in the brain - 
particularly in terms of neurodegenerative diseases remains unresolved. 
4.3 Microglial cells as a human model system to study 
xenosialitis in LOAD 
Since extensive species differences exist, this report primarily aims at maintaining a 
“human-like” culture model. Cells were cultured in either serum-deficient medium 
(SDm) or Neu5Ac-supplemented medium (Acm) as controls which represent a 
human native sialic acid environment. In parallel, cells were treated with Neu5Gc-
supplemented medium (GCm), to study the influence of Neu5Gc incorporation on 
immune cell functions. Finally, to mimic the early environment preceding clinically 
confirmed AD, cells were chronically exposed to nanomolar concentrations of Aβ. 
The concentration of Aβ used for chronic treatment was intentially chosen to be 
dramatically lower than typically used in studies with regards to AD research. 
Previous studies which describe an inflammatory response from immune cells in 
response to Aβ use concentrations of 2.5 µM (Milton et al. 2008), 5 µM (Parajuli et al. 
2013) and above. However, early in disease onset, Aβ is not present as highly 
concentrated wide-spread plaques but rather deposited as puncta in the form of 
monomers or oligomers (Hong et al. 2016).  
4.3.1 Microglial cells as a human model system 
The first aim of this project was to establish a stable and proliferative human 
microglial cell line as a human specific model system cultured in serum-free medium. 
To this end, human induced pluripotent stem (iPS) cells were differentiated into a 
microglial cell line (SdMic1 and SdMic2). However, the obtained lines proved to be 
genetically instable. Karyotyping studies indicated that the microglial lines carried 
increased chromosomal numbers in comparison to the iPS cells from which they 
were generated. Further analysis with techniques such as fluorescence in situ 
hybridization (FISH) could help identify the specific chromosomes that have been 
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duplicated. Although the discrepancies in chromosomes were not specifically 
identified, previous publications have also described instabilities in iPS cultures and 
their derivatives (Mayshar et al. 2010)(Varela et al. 2012). Further confirmation of 
genetic instability of SdMic lines was observed from SNP analysis. The abberent 
reads can be attributed to the increased chromosomal numbers of the cell lines. 
Therefore, while the SdMic lines were proliferative and could be easily expanded for 
molecular studies, the genetic instability made them an inadequate model system. In 
order to obtain genetically stable microglial cells, optimizations to the previously 
described protocol were made by including quality controls such as routine in-house 
STR analysis runs (Cooper et al. 2007). Further optimizations included culturing stem 
cells on a matrix layer and screening for KDR+CD235a+ population in the embryonic 
body (EB) stage. The percentage of double positive cells represents the embryonic 
hematopoiesis population which is known to give rise exclusively to microglial cells of 
the CNS (Ginhoux et al. 2010). In addition, stimulation of myeloid progenitors and 
microglial precursors by IL34 and MCSF aimed at supporting their development. The 
obtained microglial cells (iPSdM9) were positively indentified as microglia by their 
heritage (namely KDR+CD235a+ population) and the expression of typical markers 
such as IBA-1, CD11b and TREM2. Of all the cells identified by DAPI staining, only a 
modest population was positive for the above mentioned markers. This non-
homogenous population is due to the low microglial cell numbers obtained in the 
differentiation plates. The few thousand microglia harvested were manually picked 
using a micropipette and therefore other cells types besides microglia were also 
present. Since the microglia are not highly proliferative, they do not easily overgrow 
the other cell types to develop a homogenous cell line. Further optimization is 
required to obtain higher quantities of microglia that could represent an in vitro 
human model system, sufficient for molecular studies. Limitations of low cell numbers 
can be overcome by upscaling the differentiation, however, efficiency of 
differentiation could be bettered by increasing the proportion of KDR+CD235a+ 
population in the EB stage, for example by activating wnt pathway. While direct 
differentiation from stem cells to microglial cells is the most efficient option, the 
disadvantage includes the absence of neural input during microglial maturity that 
occurs in vivo. By including an EB development stage, both neural and myeloid 
progenitors develop in the same environment. Neuronal and astrocyte cell types are 
found in the differentiation plate alongside microglial cells. The cross-talk between 
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microglia and its neighboring neural cell types can provide vital signals to mature 
microglial cells. Finally, increased stimulation of colony stimulation factor receptor is a 
potential target to improve microglial proliferation.  
4.3.2 Influence of Neu5Gc on immune cell functions 
Validation of experimental setup 
Due to limitations in cell numbers of iPSdM9 microglial cells, THP1 monocyte-derived 
macrophages were substituted as a human model system to study the influence of 
incorporated Neu5Gc on immune cell functions in general, and SIGLEC3 signaling in 
particular. THP1 cells express surface markers typically found in both microglia and 
macrophages and well represents the human species specific immune cell type. The 
capability of human cells to metabolically incorporate Neu5Gc has been previously 
shown by publications and was further confirmed in this thesis (Tangvoranuntakul et 
al. 2003)(Bardor et al. 2005). Presence of Neu5Gc on the cell surface after culturing 
in GCm was confirmed by flow cytometry analysis using a specific anti-Neu5Gc 
antibody. Furthermore, chronic treatment of cells with Aβ significantly increased the 
detection of Neu5Gc on the cell surface. This indicates that the Aβ treatment was 
identified by the immune cells, which respond by increasing the sialic acids on the 
cell surface. Of the total Neu5Gc incorporated, xCGE-LIF identified that around 1 % 
was present in the form of glycoproteins (section 3.4.1). Therefore, it can be 
assumed that the majority of Neu5Gc is present in the form of glycolipids. The fact 
the sialic acids are primarily found onon glycolipids has been previously described by 
Schnaar and colleagues (Schnaar et al. 2014). Nevertheless, Neu5Gc isolated from 
glycolipids must also be measured by xCGE-LIF for confirmation. The incorporated 
Neu5Gc was shown to cause wide-scale dysregulation of several immune processes. 
RNA sequencing identified that over 1400 genes were differentially expressed in 
GCm cultured cells in combined comparison to SDm and ACm cultured cells. 
Interestingly, the pathways that were highlighted as being dysregulated include cell 
signaling, regulation of immune responses, regulation of response to stimuli and 
migration (section 3.4.2). This dysregulation found in GCm cultured immune cells 
indicates a proinflammatory phenotype, which is appreciable when compared to 
studies describing xenosialitis caused by Neu5Gc.  
RNA sequencing established that Neu5Gc incorporation pushed immune cells 
towards a proinflammatory phenotype. Therefore, the question arose; Which 
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pathways mediate the negative effects of Neu5Gc? Since Neu5Gc is a monosialic 
acid, the sialic acid binding receptor SIGLEC3 came into focus. Most interestingly, 
polymorphisms of SIGLEC3 have been associated with LOAD. Although Neu5Gc is 
no longer a native human sialic acid, SIGLEC3 can bind Neu5Gc (Blixt et al. 2003). 
The capacity of SIGLEC3 to bind Neu5Gc was further confirmed in this thesis by flow 
cytometry analysis using SIGLEC3 Fc-fusion protein. SIGLEC3 Fc-fusion protein 
could bind both ACm and GCm cultured cells to the same extent. Binding of the Fc-
fusion protein was futher increased when the cells were chronically treated with Aβ, 
in both ACm and GCm culture conditions (section 3.4.3). This data correlates well 
with the increased Neu5Gc detection in cells chronically treated with Aβ, in 
comparison to control cells (section 3.4.1). Therefore, an increase in ligands on the 
cell surface leads to an increase in protein binding.  
Influence of Neu5Gc on SIGLEC3 signaling 
Inhibitory receptors of the SIGLEC family and their downstream signaling are 
important in maintaining homeostasis (Johnson et al. 2013)(reviewed by Linnartz et 
al. 2010). SIGLECs are known to bind sialic acids on their own cell surface by means 
of so-called cis interactions (Crocker et al. 2007). SIGLECs bound in cis maintain 
homeostasis by propagating a baseline inhibition signal. In this thesis, the 
percentage of cis interacting SIGLEC3 was identified by taking advantage of the 
various SIGLEC3 antibodies available. Two clones of SIGLEC3 antibodies bind at 
two different epitopes; clone WM53 binds at a unique epitope that is not obstructed 
irrespective of ligand binding to SIGLEC3 and HIM3-4 clone binds an epitope that is 
proximal to ligand-binding epitope and therefore, can only bind if the protein is not 
ligand bound. Therefore, the clone WM53 determines the total SIGLEC3 while the 
clone HIM3-4 determines unbound / free SIGLEC3. By subtracting the total SIGLEC3 
from free SIGLEC3 (WM53 - HIM3-4), the percentage of cells with cis-interacting 
SIGLEC3 can be calculated. For further detail, the ratio between bound to total 
SIGLEC3 was calculated. Increase of SIGLEC3 bound to ligand would indicate an 
increase in inhibitory signaling. While SDm and ACm cultured untreated cells 
exhibited comparable ratios of cis-bound SIGLEC, these ratios significantly increased 
in both cases when chronically treated with Aβ (section 3.4.3). An increase in 
inhibitory signaling upon Aβ treatment could indicate an attempt to modulate the 
activation of the cell upon stimulation. GCm cultured cells constitutively exhibited 
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more bound SIGLEC3, which was not further increased upon binding to Aβ (section 
3.4.3). By similar logic, the cells could also be increasing SIGLEC3 signaling to 
modulate cellular activation. However, in the case of GCm cultured cells, two more 
possibilities should be taken into consideration. First, since human sialidases are 
incapable of efficiently turning over Neu5Gc, the SIGLEC3 could simply be 
persistently bound due to the continual presence of the sialic acid. Since Neu5Gc-
bound SIGLEC3 does not propagate inhibitory signaling (section 3.4.4), the second 
possibility could be an increase in SIGLEC3 binding to compensate for the lack of 
downstream SIGLEC3 signaling by the inappropriate binding of Neu5GC.  
Downstream signaling of SIGLEC3 was determined by the recruitment of SHP1 to 
the protein. Co-immunoprecipitation of SIGLEC3 and SHP1 determined that 
significantly less SHP1 was recruited in the case of GCm cultured cells (section 
3.4.4). Insufficient recruitment of SHP1 indicates that SIGLEC3 inhibitory signaling is 
not propagated when Neu5Gc is incorporated. In conclusion, SIGLEC3 Fc-fusion 
protein analysis confirms that Neu5Gc can bind SIGLEC3 but western blot analysis 
determines that this binding does not propagate an inhibitory signaling due to a 
reduced recuitment of the downstream molecule, SHP1.  
Upon identification of dysregulated SIGLEC3 signaling due to Neu5Gc, a SIGLEC3 
knockout (SIG3 KO) cell line was introduced as a control in comparison to wildtype 
(WT) cells. Differences observed between ACm cultured WT cells and GCm cultured 
WT cells could be compared to the respective SIG3 KO cells to determine whether 
presence of SIGLEC3 attenuates or exacerbates these differences.  
Influence of Neu5Gc on functional characteristics of macrophages 
First, all samples were tested for their metabolic activity by MTT assay. The 
metabolic rate was not altered within the cell type, among the different culture and 
treatment conditions. However, cells of each SIG3 KO culture condition exhibited 
significantly less metabolism than their corresponding WT samples (section 3.4.5). 
The fact that the metabolism was also decreased in the control culture conditions, in 
SIG3 KO cells compared to WT cells, indicates a genotype specific connection. SIG3 
KO cells could be downregulating metabolic processes as a compensation 
mechanism to the loss of an important homeostatic inhibitory signaling pathway. 
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However, analysis by RNA sequencing are required for further insights to the 
activatory status of the SIG3 KO cells.  
Functional read outs studied in the two cell lines (WT and SIG3 KO), under the 
different culture conditions (table 1) included apoptosis assay, phosphorylation of 
ERK, production of ROS, phagocytosis assay, quantitative real time PCR for 
complement components and surface marker analysis of LOAD-associated TREM2. 
In confirmation with RNA sequencing analysis, all functional read outs indicated that 
GCm cultured cells were more activated than control cells. Incorporation of Neu5Gc 
in WT cells significantly increased apoptosis, while chronic treatment with Aβ tended 
to increase apoptosis rate, this tendency remained insignificant. Most interestingly, 
SIG3 KO cells did not modulate their apoptosis rates, irrespective of culture 
conditions and treatments. Therefore, knockout out SIGLEC3 rescues the cells from 
Neu5Gc induced apoptosis (section 3.4.6). An indirect measurement of SIGLEC3 
signaling was obtained by detecting the phosphorylation status of downstream 
activatory molecule, ERK. ERK phosphorylation indicates propagation of an 
activatory signal. Although, it must be noted that several activation pathways can 
lead to activatory signaling. However, ERK is a strong candidate downstream of the 
activatory pathway that could be modulated by SHP1 of the SIGLEC3 inhibitory 
pathway (figure 4). Chronic treatment of ACm cultured WT cells was not sufficient to 
increase ERK phosphorylation. Similarly, GCm culture of WT cells in untreated 
condition was also insufficient for inducing phosphorylation of ERK. However, a 
combination of GCm culture and chronic treatment with Aβ significantly increased the 
phosphorylation of ERK in WT cells. In the case of SIG3 KO cells, phosphorylated 
ERK was constitutively increased in ACm cultured cells (section 3.4.7). Since loss of 
SIGLEC3 signaling elicits an increase in ERK phosphorylation, this outcome further 
supports the statement above, which claims that ERK is a strong candidate that can 
be modulated via SIGLEC3 signaling. As seen in apoptosis assay, phosphorylation of 
ERK could also not be modulated by culture conditions or treatments in SIG3 KO 
cells. While the differences between GCm WT and GCm SIG3 KO cells were not 
significant, a significant difference in ACm culture condition was seen. One of the 
most critical read outs is the measurement for the production of ROS. Production of 
ROS is toxic to cells and chronic production can cause wide-spread cellular damage 
and ultimately neurodegeneration. Fitting with the activated status of GCm cultured 
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WT cells, Neu5Gc incorporation significantly increased ROS production in 
comparison to ACm cultured WT cells. Most interestingly, chronic treatement with Aβ 
in ACm cultured WT cells did not induce an increase in ROS production. This data is 
in contrast to several publications which utilise high concentrations of fibrillary Aβ to 
elicit a proinflammatory response. In this thesis, the concentration of Aβ that has 
been used was intentially chosen to be minimal, yet chronic. Although chronic 
treatment in this sample did not elicit increased ROS, cells were nevertheless 
stimulated to upregulate phagocytosis upon stimulation (as further described below 
and in section 3.4.9), which indicates an appropriate immune response. Chronic 
treatment in GCm cultured WT cells produced comparable quatities of ROS as 
untreated cells under the same condition. The SIG3 KO cells were once again stable 
in ROS production across all culture conditions and treatments (section 3.4.8). 
Therefore, loss of SIGLEC3 signaling attenuated the detrimental effects of Neu5Gc 
incorporation. Although chronic treatment of ACm cultured WT cells did not increase 
the production of ROS, this does not indicate that the cells cannot be activated upon 
stimulation. On the contrary, acute stimulation of cells with high concentrations of Aβ 
did elicit a phagocytic response. This increase in phagocytosis occurs in an anti-
inflammatory manner, namely in the absence of ROS. Only the WT cells cultured in 
GCm were phagocytic in a proinflammatory manner and acute stimulation with high 
quantities of Aβ did not induce an increase in phagocytosis. The inability of GCm 
cultured WT cells to appropriately respond to stimulation, along with the 
consititutively high production of ROS further confirms the detrimental effects of 
Neu5Gc incorporation. Interestingly, the benefits of the lack of SIGLEC3 signaling 
was furthered by their consitutively high phagocytosis capacity. Interestingly, SIG3 
KO cells were significantly more phagocytic than WT cells under any culture 
condition or treatment (section 3.4.9). The high phagocytosis capacity of SIG3 KO 
cells, along with their capacity to inhibit ROS production in the presence of Neu5Gc, 
speaks volumes for the beneficial effects of knocking out SIGLEC3 signaling to 
attentuate its association with AD risk.  
Phagocytosis is an important function of immune cells that is lacking in LOAD and 
chronic activation is a feature that is in excess. Increased activity of the classical 
complement cascade has been previously identified in models for AD. Therefore, the 
influence of Neu5Gc on components of the classical complement pathways came 
into focus. To this end, quantitative real time PCR analysis of the complement 
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components c1q and c3 were carried out. C1q is the initiator component of, and 
exclusive to the classical complement cascade. On the other hand, C3 is a central 
component upon which the classical, the lectin as well as the alternative complement 
cascades merge. Transcriptions of both C1q as well as C3 were significantly 
increased in GCm cultured WT cells, in comparison to ACm cultured WT cells. SDm 
cultured WT cells tended to be comparable to ACm cultured WT cells albeit without 
significant differences. Therefore, Neu5Gc could be interpreted as stimulation for the 
classical complement pathway in LOAD. The SIG3 KO cells tended to transcribe 
lower quantities of both c1q and c3 components than WT cells of the corresponding 
culture condition and treatment. Nevertheless, as seen before, Neu5Gc could not 
induce an increase in c1q or c3 transcription in SIG3 KO cells (section 3.4.10). 
Chronic treatment with Aβ did not induce significant differences in either cell line or 
culture conditions. However, chronic treatment with Aβ exclusively modulated the 
next read out, namely TREM2 surface marker expression. Modulation of TREM2 
surface marker expression has been extensively studied with respect to Aβ plaques 
and by association to LOAD. TREM2 is of particular interest since downstream 
signaling of TREM2 mediates phagocytosis (figure 4). Microglial cells that are 
proximal to plaques notoriously upregulate TREM2 expression although the cells are 
not phagocytically active enough to clear away the Aβ plaques. Conversely, microglia 
distal to plaques have less TREM2 expression on the cell surface. Several 
publications emphasize on the importance of functional TREM2 to cope with Aβ 
plaque clearance in LOAD (Wang et al. 2015)(Yeh et al. 2016). Furthermore, GWAS 
have associated mutations in TREM2 with increased LOAD risk (Guerreiro et al. 
2013). Most interestingly, a recent paper by Chan and colleagues have identified that 
SIGLEC3 can modulate TREM2 expression (Chan et al. 2015a), which can be critical 
considering the dysregulation of SIGLEC3 signaling in the presence of Neu5Gc. In 
this thesis, TREM2 surface marker expression was found to be significantly 
upregulated in SDm and ACm cultured WT cells, only when chronically treated with 
Aβ. On the other hand, WT cells cultured in GCm could not increase TREM2 
expression upon chronic treatment with Aβ. The incapability to respond to the 
presence of Aβ further confirms the dysregulated immune cell response to stimuli in 
the presence of Neu5Gc. The positive correlation between SIGLEC3 and TREM2 
(Chan et al. 2015b) was confirmed by the significantly lower expression of TREM2 in 
all SIG3 KO culture and treatment conditions (section 3.4.11). While knocking out 
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SIGLEC3 proved to be beneficial in all read outs described above, the drastic 
reduction in TREM2 could be a critical point to consider when developing therapies.  
4.4 A hypothesis on the associations between LOAD 
incidence, xenosialitis and SIGLEC3 
Based on the cummulative results described above, I present a hypothesis that aims 
at explaining the influence of xenosialitis and SIGLEC3 signaling on LOAD incidence. 
Studies supported by the World Health Organization (WHO) show a clear tendency 
towards increased LOAD deaths in populations of industralized countries over 
populations in the asian and african continents  (www.worldlifeexpectancy.com). Data 
obtained were appropriately standardized to age, and therefore improvements in 
health care and increased life expectancy have not artifically influenced this data. 
One major difference among the various nations is diet. Studies show that following a 
mediterranean diet decreases LOAD risk (as reviewed by (Lin & Scott 2012)), 
however, a western diet causes chronic glial activation (Graham et al. 2016). Glial 
activation leading to chronic inflammation is a well documented feature of LOAD (Lull 
& Block 2011)(Doens et al. 2014). A western diet is defined as being rich in red meat 
and milk products and is a source of xenosialitis-inducing Neu5Gc sialic acids 
(Philpott, Tom (April 5, 2011). "The American diet in one chart, with lots of fats and 
sugars". Industrial Agriculture. Grist. Retrieved December 1, 2011.). Therefore, this 
hypothesis suggests that western diet driven xenosialitis causes inflammation in 
general, and dysfunctional SIGLEC3 signaling in particular, to increase LOAD risk. 
LOAD risk is only higher in caucasian populations expressing full length SIGLEC3. 
This data reiterates the fact that full length SIGLEC3 only exacerbates LOAD in 
western diet environment, which is a source of Neu5Gc. Since asians and africans do 
not follow a strict western diet, the dietary supply of Neu5Gc is low and inconsistent. 
SIGLEC3 variants can either be beneficial or detrimental depending on the 
populations in which they are expressed. There are two isoforms of SIGLEC3; full 
length isoform, like the name mentions is the long version of SIGLEC3 as previously 
described in this thesis, and exon2 spliced isoform which lacks the sialic acid binding 
domain (Hernández-Caselles et al. 2006)(Malik et al. 2013). Therefore, exon2 spliced 
SIGLEC3 cannot mediate inhibitory signaling. Interestingly, the well documented risk 
allele of SIGLEC3 leads to transcription ratios of 9:1 in favor of full length SIGLEC3 
isoform. On the other hand, the so-called protective allele modifies the ratio of 
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expression of SIGLEC3 isoforms full length and exon2 spliced to 7:3, respectively 
(Schwarz, Springer, et al. 2015). In conclusion, the expression of a functional full 
length version of SIGLEC3 at a higher degree is detrimental in comparison to exon2 
spliced SIGLEC3. Researchers in the field interpret this outcome as follows - loss or 
reduction of SIGLEC3 signaling causes increased phagocytic removal of Aβ and 
ultimately lowers LOAD risk (as reviewed by (Angata 2014)). Intriguingly, the overall 
expression of full length SIGLEC3 is higher in humans than in our closest relatives, 
chimpanzees and bonobos. This upregulation of the homeostatic receptor is unique 
to the members of the genus Homo. In addition, the protective SIGLEC3 allele is 
uniquely found only in modern humans, being absent in our ancestors of the same 
genus (Schwarz, Springer, et al. 2015). Therefore, the onset of SIGLEC3 protective 
allele is a rather recent event that arose out of necessity. The incidence of protective 
allele is highest in the Caucasian populations that consume western diet (figure 21) 
and is least prevalent in Asian and African populations. Therefore, the association 
between western diet derived Neu5Gc detrimentally affecting SIGLEC3 signaling to 
increase LOAD risk could have been the eminent trigger that supported the 
emergence of the protective allele of SIGLEC3.  
In conclusion, the inflammatory effects of Neu5Gc, which is already linked to cancer 
progression, could also be the initiator of chronic activation and dysregulated immune 
responses in microglial cells. The malfunctioning inhibitory SIGLEC3 may further 
exacerbate disease progression leading to imbalances in homeostasis and a 
persistent pathological environment. Malfunctioning microglia cannot respond to 
stimuli such as Aβ, which accumulate into plaques when left unchecked (figure 22). 
Understanding the role of all components from a molecular level to a pandemic level 
is crucial for the development of therapies that would hinder disease progression, 
outside of genetic susceptibilities. On a final note, all data point towards the benefits 
of a diet low in red meat and milk products. Such a dietary recommendation is 
already in place as supplement to medication in the case of rheumatoid arthritis, and 
should be sincerely considered for clinically diagnosed LOAD patients.  
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Figure 21: Global association between red meat consumption, AD risk and 
prevalence of SIGLEC3 protective allele. Epidemiological studies identified 
industrialized nations as the highest consumers and Asian and African continents as 
the lowest consumers of red meat. Research supported by the world health 
organization have identified the American and Australian continent as having the 
highest incidence of late onset Alzheimer’s disease (LOAD), with Europe with a 
comparatively decreased incidence and Asian and African continents with the lowest 
incidence. Studies in the field of LOAD have identified highest prevalence of 
SIGLEC3 protective allele in Caucasian populations, followed by East-Asians and 
finally Africans and South-East Asians. Sources: blank world map: 
https://www.printableworldmap.net/. Modified to represent data on red meat 
consumption:  protective allele frequency data: (Schwarz, Springer, et al. 2015) 
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Figure 22: Neu5Gc induced microglial malfunctioning causes inflammation and 
can exacerbate LOAD pathology. Incorporation of Neu5Gc over time leads to an 
accumulation of this sialic acid. Accumulated sialic acid activates the complement 
cascade and causes radical bursts in the form of reactive oxygen species. 
Chronically inflammatory microglia forgo their responses to stimuli and fail to clear 
away deposited amyloid beta (Aβ). Left unchecked, Aβ accumulates into plaques 
which further activate surrounding glial cells. A vicious cycle of activation, 
inflammation and finally neurodegeneration develops.   
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5. Summary 
Neuroinflammation and complement activation is believed to occur decades before 
clinical diagnosis of late onset Alzheimer’s disease (LOAD). This project aimed to 
clarify the molecular environment that might modulate microglial activation prior to 
clinical diagnosis of LOAD. A human model system was used to study the human 
species-specific receptor sialic acid binding immunoglobulin-type lectin 3 (SIGLEC3) 
that has been associated with LOAD. SIGLEC3 can bind acetylated as well as 
glycosylated sialic acid (Neu5Ac and Neu5Gc, respectively). Neu5Gc cannot be 
produced by humans, but is metabolically incorporated in human cells after 
consumption of red meat or dairy products. Neu5Gc is known to cause xenosialitis, 
which involves an immune reaction in response to Neu5Gc incorporation.  
First, human microglial cells (iPSdM9) were successfully differentiated from induced 
pluripotent stem (iPS) cells as a potential human model system to study SIGLEC3. 
Data indicate that the iPSdM9 microglial cells are capable of phagocytosis and 
proliferation. Furthermore, iPSdM9 cells positively express typical surface markers, 
namely IBA-1, TREM2 and CD11b. However, the limited cell numbers obtained 
hindered their use as a model system for molecular studies. For this reason, THP1 
monocyte-derived macrophages were used as a surrogate human model system to 
study the role of SIGLEC3. 
Effective incorporation of Neu5Gc into the THP1 macrophages by medium 
supplementation was confirmed by flow cytometry and xCGE-LIF analysis. RNA 
sequencing analysis established that incorporated Neu5Gc caused broad cellular 
dysregulation in comparison to cells cultured in Neu5Ac-supplemented medium, with 
more than 1400 differentially expressed genes. The particular pathways affected 
include cellular signaling, regulation of immune responses, immune cell development 
and responses to stimuli. While flow cytometry analysis using SIGLEC3 Fc-fusion 
proteins confirmed SIGLEC3 binding to Neu5Gc, western blot data determined that 
inhibitory signaling by SIGLEC3 was not effectively propagated. Therefore, Neu5Gc 
induced disruption of homeostatic SIGLEC3 signaling was hypothesized to cause 
malfunctioning of immune cells.  
THP1 macrophages cultured in Neu5Ac-supplemented medium responded to Aβ 
treatment by increasing phagocytosis in a non-inflammatory manner. However, the 
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cells cultured in Neu5Gc-supplemented medium constitutively exhibited higher 
phagocytosis, accompanied by reactive oxygen species production. Furthermore, Aβ 
treatment of these cells did not increase phagocytosis, hinting at the dysfunctional 
immune response of cells carrying incorporated Neu5Gc. Additionally, real-time PCR 
analysis of classical complement cascade components revealed increased 
transcription of the complement components - c1q and c3, in cells cultured in 
Neu5Gc-supplemented medium. Taken together, Neu5Gc culture causes constitutive 
activation of macrophages. Interestingly, knocking out SIGLEC3 attenuates the 
Neu5Gc induced inflammatory characteristics but maintains increased phagocytosis 
upon Aβ treatment.  
In conclusion, food-derived Neu5Gc is a possible candidate as an initiator for pre-
clinical microglial dysfunction. Neu5Gc disrupts microglial immune responses and 
chronically induces radical production. Knocking out SIGLEC3 attenuates Neu5Gc 
induced inflammation and provides a possible therapeutic target against LOAD 
onset.  
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